An element of the rare earth family of metals. It has the atomic symbol Y, atomic number 39, and atomic weight 88.91. In conjunction with other rare earths, yttrium is used as a phosphor in television receivers and is a component of the yttrium-aluminum garnet (YAG) lasers.
Unstable isotopes of yttrium that decay or disintegrate emitting radiation. Y atoms with atomic weights 82-88 and 90-96 are radioactive yttrium isotopes.
Stable yttrium atoms that have the same atomic number as the element yttrium, but differ in atomic weight. Y-89 is the only naturally occurring stable isotope of yttrium.
Isotopes that exhibit radioactivity and undergo radioactive decay. (From Grant & Hackh's Chemical Dictionary, 5th ed & McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Neodymium. An element of the rare earth family of metals. It has the atomic symbol Nd, atomic number 60, and atomic weight 144.24, and is used in industrial applications.
Lasers which use a solid, as opposed to a liquid or gas, as the lasing medium. Common materials used are crystals, such as YAG (YTTRIUM aluminum garnet); alexandrite; and CORUNDUM, doped with a rare earth element such as a NEODYMIUM; ERBIUM; or HOLMIUM. The output is sometimes additionally modified by addition of non-linear optical materials such as potassium titanyl phosphate crystal, which for example is used with neodymium YAG lasers to convert the output light to the visible range.
Unstable isotopes of zinc that decay or disintegrate emitting radiation. Zn atoms with atomic weights 60-63, 65, 69, 71, and 72 are radioactive zinc isotopes.
The use of photothermal effects of LASERS to coagulate, incise, vaporize, resect, dissect, or resurface tissue.
Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).
Unstable isotopes of indium that decay or disintegrate emitting radiation. In atoms with atomic weights 106-112, 113m, 114, and 116-124 are radioactive indium isotopes.
The coagulation of tissue by an intense beam of light, including laser (LASER COAGULATION). In the eye it is used in the treatment of retinal detachments, retinal holes, aneurysms, hemorrhages, and malignant and benign neoplasms. (Dictionary of Visual Science, 3d ed)
Erbium. An element of the rare earth family of metals. It has the atomic symbol Er, atomic number 68, and atomic weight 167.26.
Method for assessing flow through a system by injection of a known quantity of radionuclide into the system and monitoring its concentration over time at a specific point in the system. (From Dorland, 28th ed)
Methods of delivering drugs into a joint space.
Procedures performed to remove CAPSULE OPACIFICATION that develops on the POSTERIOR CAPSULE OF THE LENS following removal of a primary CATARACT.
Ytterbium. An element of the rare earth family of metals. It has the atomic symbol Yb, atomic number 70, and atomic weight 173. Ytterbium has been used in lasers and as a portable x-ray source.
Unstable isotopes of strontium that decay or disintegrate spontaneously emitting radiation. Sr 80-83, 85, and 89-95 are radioactive strontium isotopes.
Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.
A group of elements that include SCANDIUM; YTTRIUM; and the LANTHANOID SERIES ELEMENTS. Historically, the rare earth metals got their name from the fact that they were never found in their pure elemental form, but as an oxide. In addition they were very difficult to purify. They are not truly rare and comprise about 25% of the metals in the earth's crust.
Unstable isotopes of krypton that decay or disintegrate emitting radiation. Kr atoms with atomic weights 74-77, 79, 81, 85, and 87-94 are radioactive krypton isotopes.
Scandium. An element of the rare earth family of metals. It has the atomic symbol Sc, atomic number 21, and atomic weight 45.
Unstable isotopes of sodium that decay or disintegrate emitting radiation. Na atoms with atomic weights 20-22 and 24-26 are radioactive sodium isotopes.
The spontaneous transformation of a nuclide into one or more different nuclides, accompanied by either the emission of particles from the nucleus, nuclear capture or ejection of orbital electrons, or fission. (McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)
Unstable isotopes of barium that decay or disintegrate emitting radiation. Ba atoms with atomic weights 126-129, 131, 133, and 139-143 are radioactive barium isotopes.
The production of an image obtained by cameras that detect the radioactive emissions of an injected radionuclide as it has distributed differentially throughout tissues in the body. The image obtained from a moving detector is called a scan, while the image obtained from a stationary camera device is called a scintiphotograph.
Unstable isotopes of tin that decay or disintegrate emitting radiation. Sn atoms with atomic weights 108-111, 113, 120-121, 123 and 125-128 are tin radioisotopes.
Zirconium. A rather rare metallic element, atomic number 40, atomic weight 91.22, symbol Zr. (From Dorland, 28th ed)
Unstable isotopes of carbon that decay or disintegrate emitting radiation. C atoms with atomic weights 10, 11, and 14-16 are radioactive carbon isotopes.
Unstable isotopes of iron that decay or disintegrate emitting radiation. Fe atoms with atomic weights 52, 53, 55, and 59-61 are radioactive iron isotopes.
A collective term for interstitial, intracavity, and surface radiotherapy. It uses small sealed or partly-sealed sources that may be placed on or near the body surface or within a natural body cavity or implanted directly into the tissues.
Unstable isotopes of copper that decay or disintegrate emitting radiation. Cu atoms with atomic weights 58-62, 64, and 66-68 are radioactive copper isotopes.
Unstable isotopes of phosphorus that decay or disintegrate emitting radiation. P atoms with atomic weights 28-34 except 31 are radioactive phosphorus isotopes.
High energy POSITRONS or ELECTRONS ejected from a disintegrating atomic nucleus.
An optical source that emits photons in a coherent beam. Light Amplification by Stimulated Emission of Radiation (LASER) is brought about using devices that transform light of varying frequencies into a single intense, nearly nondivergent beam of monochromatic radiation. Lasers operate in the infrared, visible, ultraviolet, or X-ray regions of the spectrum.
A synovial hinge connection formed between the bones of the FEMUR; TIBIA; and PATELLA.
The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, atomic number 43, and atomic weight 98.91. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years.
Unstable isotopes of mercury that decay or disintegrate emitting radiation. Hg atoms with atomic weights 185-195, 197, 203, 205, and 206 are radioactive mercury isotopes.
A gamma-emitting radionuclide imaging agent used for the diagnosis of diseases in many tissues, particularly in the gastrointestinal system, liver, and spleen.
Stable cesium atoms that have the same atomic number as the element cesium, but differ in atomic weight. Cs-133 is a naturally occurring isotope.
Unstable isotopes of cerium that decay or disintegrate emitting radiation. Ce atoms with atomic weights 132-135, 137, 139, and 141-148 are radioactive cerium isotopes.
Stable cobalt atoms that have the same atomic number as the element cobalt, but differ in atomic weight. Co-59 is a stable cobalt isotope.
Hafnium. A metal element of atomic number 72 and atomic weight 178.49, symbol Hf. (From Dorland, 28th ed)
Unstable isotopes of gold that decay or disintegrate emitting radiation. Au 185-196, 198-201, and 203 are radioactive gold isotopes.
Techniques for labeling a substance with a stable or radioactive isotope. It is not used for articles involving labeled substances unless the methods of labeling are substantively discussed. Tracers that may be labeled include chemical substances, cells, or microorganisms.
Unstable isotopes of lead that decay or disintegrate emitting radiation. Pb atoms with atomic weights 194-203, 205, and 209-214 are radioactive lead isotopes.
Any diagnostic evaluation using radioactive (unstable) isotopes. This diagnosis includes many nuclear medicine procedures as well as radioimmunoassay tests.
Stable zinc atoms that have the same atomic number as the element zinc, but differ in atomic weight. Zn-66-68, and 70 are stable zinc isotopes.
Unstable isotopes of sulfur that decay or disintegrate spontaneously emitting radiation. S 29-31, 35, 37, and 38 are radioactive sulfur isotopes.
Unstable isotopes of cadmium that decay or disintegrate emitting radiation. Cd atoms with atomic weights 103-105, 107, 109, 115, and 117-119 are radioactive cadmium isotopes.
Astatine. A radioactive halogen with the atomic symbol At, atomic number 85, and atomic weight 210. Its isotopes range in mass number from 200 to 219 and all have an extremely short half-life. Astatine may be of use in the treatment of hyperthyroidism.
Small uniformly-sized spherical particles, of micrometer dimensions, frequently labeled with radioisotopes or various reagents acting as tags or markers.
Lutetium. An element of the rare earth family of metals. It has the atomic symbol Lu, atomic number 71, and atomic weight 175.
The inner membrane of a joint capsule surrounding a freely movable joint. It is loosely attached to the external fibrous capsule and secretes SYNOVIAL FLUID.
Rhenium. A metal, atomic number 75, atomic weight 186.2, symbol Re. (Dorland, 28th ed)
Samarium. An element of the rare earth family of metals. It has the atomic symbol Sm, atomic number 62, and atomic weight 150.36. The oxide is used in the control rods of some nuclear reactors.
Antibodies produced by a single clone of cells.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
Pollutants, present in soil, which exhibit radioactivity.
Unstable isotopes of bromine that decay or disintegrate emitting radiation. Br atoms with atomic weights 74-78, 80, and 82-90 are radioactive bromine isotopes.
Detection and counting of scintillations produced in a fluorescent material by ionizing radiation.
Leakage and accumulation of CEREBROSPINAL FLUID in the subdural space which may be associated with an infectious process; CRANIOCEREBRAL TRAUMA; BRAIN NEOPLASMS; INTRACRANIAL HYPOTENSION; and other conditions.
Stable calcium atoms that have the same atomic number as the element calcium, but differ in atomic weight. Ca-42-44, 46, and 48 are stable calcium isotopes.
Liquid, solid, or gaseous waste resulting from mining of radioactive ore, production of reactor fuel materials, reactor operation, processing of irradiated reactor fuels, and related operations, and from use of radioactive materials in research, industry, and medicine. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Normal human serum albumin mildly iodinated with radioactive iodine (131-I) which has a half-life of 8 days, and emits beta and gamma rays. It is used as a diagnostic aid in blood volume determination. (from Merck Index, 11th ed)
Unstable isotopes of ruthenium that decay or disintegrate emitting radiation. Ru atoms with atomic weights 93-95, 97, 103, and 105-108 are radioactive ruthenium isotopes.
Techniques used to determine the age of materials, based on the content and half-lives of the RADIOACTIVE ISOTOPES they contain.
Unstable isotopes of selenium that decay or disintegrate emitting radiation. Se atoms with atomic weights 70-73, 75, 79, 81, and 83-85 are radioactive selenium isotopes.
Positively charged particles composed of two protons and two NEUTRONS, i.e. equivalent to HELIUM nuclei, which are emitted during disintegration of heavy ISOTOPES. Alpha rays have very strong ionizing power, but weak penetrability.
A class of organic compounds containing a ring structure made up of more than one kind of atom, usually carbon plus another atom. The ring structure can be aromatic or nonaromatic.
A gamma-emitting radionuclide imaging agent used for the diagnosis of diseases in many tissues, particularly in the gastrointestinal system, cardiovascular and cerebral circulation, brain, thyroid, and joints.
Tungsten. A metallic element with the atomic symbol W, atomic number 74, and atomic weight 183.85. It is used in many manufacturing applications, including increasing the hardness, toughness, and tensile strength of steel; manufacture of filaments for incandescent light bulbs; and in contact points for automotive and electrical apparatus.
Atomic species differing in mass number but having the same atomic number. (Grant & Hackh's Chemical Dictionary, 5th ed)
A type of high-energy radiotherapy using a beam of gamma-radiation produced by a radioisotope source encapsulated within a teletherapy unit.
An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.

Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. (1/426)

Monoclonal antibodies (MoAb) labeled with 90Y are being used for radioimmunotherapy. Because 90Y is a beta emitter, quantitative information from imaging is suboptimal. With the concept of a "matched pair" of isotopes, 111In is used as a surrogate markerfor90Y. We evaluated the differences in biodistribution between 111In- and 90Y-labeled murine antiTac MoAb directed against the IL-2Ralpha receptor. METHODS: The antiTac was conjugated to the 2-(4-isothiocyanatobenzyl)-6-methyl-diethylenetriamine pentaacetic acid (1B4M-DTPA, also known as MX-DTPA). Nine patients with adult T-cell leukemia were treated. Patients received approximately 185 MBq (5 mCi) 111In-labeled antiTac for imaging and 185-555 MBq (5-15 mCi) 90Y-labeled antiTac for therapy. The immunoreactivity of 111In-labeled antiTac was 90%+/-6%, whereas for 90Y-labeled antiTac, it was 74%+/-12%. RESULTS: The differences in blood and plasma kinetics of the two isotopes were small. The area undemeath the blood radioactivity curve was 1.91 percentage+/-0.58 percentage injected dose (%ID) x h/mL for 111In and 1.86%+/-0.64 %ID x h/mL for 90Y. Urinary excretion of 90Y was significantly greater than that of 111In in the first 24 h (P = 0.001), but later, the excretion of 111In was significantly greater (P = 0.001 to P = 0.04). Core biopsies of bone marrow showed a mean of 0.0029+/-0.0012 %ID/g for 111In, whereas the 90Y concentration was 0.0049+/-0.0021 %ID/g. Analyses of activity bound to circulating cells showed concentrations of 500-30,000 molecules of antiTac per cell. When cell-bound activity was corrected for immunoreactive fraction, the ratio of 111In to 90Y in circulating cells was 1.11+/-0.17. Three biopsies of tumor-involved skin showed ratios of 111In to 90Y of 0.7, 0.9 and 1.1. CONCLUSION: This study shows that differences typically ranging from 10% to 15% exist in the biodistribution between 111In- and 90Y-labeled antiTac. Thus, it appears that 111In can be used as a surrogate marker for 90Y when labeling antiTac with the 1 B4M chelate, although underestimates of the bone marrow radiation dose should be anticipated.  (+info)

Distribution of yttrium 90 ferric hydroxide colloid and gold 198 colloid after injection into knee. (2/426)

Thirteen knees were injected with yttrium 90(90Y) ferric hydroxide colloid, and 12 with gold 198(198Au) colloid for treatment of persistent synovitis. Retention in the knee and uptake in lymph nodes and liver were measured by a quantitative scanning technique. There was no significant difference in the retention in the knee of the two different colloids. A tendency towards higher lymph node uptake was observed with 198Au compared with 90y. The inflammatory activity of the knee at the time of treatment may have influenced the subsequent lymph node uptake of 198Au, but not that of the 90Y, nor the overall leakage of either from the knee. 90Yferric hydroxide colloid was retained in the treated knee at least as well as other colloids which have been used for this purpose.  (+info)

Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. (3/426)

Scintigraphy with [111In-diethylenetriamine pentaacetic acid0-D-Phe1]-octreotide (DTPAOC) is used to demonstrate neuroendocrine and other somatostatin-receptor-positive tumors. Despite encouraging results, this 111In-labeled compound is not well suited for peptide-receptor-mediated radiotherapy of somatostatin-receptor-positive tumors. Another somatostatin analog, [1,4,7,10-tetraazacyclododecane-N,N',N",N'''-tetraacetic acid0, D-Phe1, Tyr3]-octreotide (DOTATOC), can be labeled with the beta-emitter 90Y in a stable manner. METHODS: We compared the distribution, kinetics and dosimetry of 111In-DTPAOC and 111In-DOTATOC in eight patients to predict the outcomes of these parameters in patients who will be treated with 90Y-DOTATOC. RESULTS: Serum radioactivity levels for the radiopharmaceuticals did not differ significantly 2-24 h after injection (P>0.05). Up to 2 h postinjection they were slightly, but significantly, lower after administration of 111In-DOTATOC (P < 0.01 at most time points). The percentage of peptide-bound radioactivity in serum did not differ after administration of either compound. Urinary excretion was significantly lower after administration of 111In-DOTATOC (P < 0.01). The visualization of known somatostatin-receptor-positive organs and tumors was clearer after administration of 111In-DOTATOC than after administration of 111In-DTPAOC. This was confirmed by significantly higher calculated uptakes in the pituitary gland and spleen. The uptake in the tumor sites did not differ significantly (P > 0.05), although in three of the four patients in whom tumor uptake could be calculated, it was higher after administration of 111In-DOTATOC. CONCLUSION: The distribution and excretion pattern of 111In-DOTATOC resembles that of 111In-DTPAOC, and the uptake in somatostatin-receptor-positive organs and most tumors is higher for 111In-DOTATOC. If 90Y-DOTATOC shows an uptake pattern similar to 111In-DOTATOC, it is a promising radiopharmaceutical for peptide-receptor-mediated radiotherapy in patients with somatostatin-receptor-positive tumors.  (+info)

High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. (4/426)

Recent studies suggest that radioimmunotherapy (RIT) with high-linear energy transfer (LET) radiation may have therapeutic advantages over conventional low-LET (e.g., beta-) emissions. Furthermore, fragments may be more effective in controlling tumor growth than complete IgG. However, to the best of our knowledge, no investigators have attempted a direct comparison of the therapeutic efficacy and toxicity of a systemic targeted therapeutic strategy, using high-LET alpha versus low-LET beta emitters in vivo. The aim of this study was, therefore, to assess the toxicity and antitumor efficacy of RIT with the alpha emitter 213Bi/213Po, as compared to the beta emitter 90Y, linked to a monovalent Fab' fragment in a human colonic cancer xenograft model in nude mice. Biodistribution studies of 213Bi- or 88Y-labeled benzyl-diethylene-triamine-pentaacetate-conjugated Fab' fragments of the murine monoclonal antibody CO17-1A were performed in nude mice bearing s.c. human colon cancer xenografts. 213Bi was readily obtained from an "in-house" 225Ac/213Bi generator. It decays by beta- and 440-keV gamma emission, with a t(1/2) of 45.6 min, as compared to the ultra-short-lived alpha emitter, 213Po (t(1/2) = 4.2 micros). For therapy, the mice were injected either with 213Bi- or 90Y-labeled CO17-1A Fab', whereas control groups were left untreated or were given a radiolabeled irrelevant control antibody. The maximum tolerated dose (MTD) of each agent was determined. The mice were treated with or without inhibition of the renal accretion of antibody fragments by D-lysine (T. M. Behr et al., Cancer Res., 55: 3825-3834, 1995), bone marrow transplantation, or combinations thereof. Myelotoxicity and potential second-organ toxicities, as well as tumor growth, were monitored at weekly intervals. Additionally, the therapeutic efficacy of both 213Bi- and 90Y-labeled CO17-1A Fab' was compared in a GW-39 model metastatic to the liver of nude mice. In accordance with kidney uptake values of as high as > or = 80% of the injected dose per gram, the kidney was the first dose-limiting organ using both 90Y- and 213Bi-labeled Fab' fragments. Application of D-lysine decreased the renal dose by >3-fold. Accordingly, myelotoxicity became dose limiting with both conjugates. By using lysine protection, the MTD of 90Y-Fab' was 250 microCi and the MTD of 213Bi-Fab' was 700 microCi, corresponding to blood doses of 5-8 Gy. Additional bone marrow transplantation allowed for an increase of the MTD of 90Y-Fab' to 400 microCi and for 213Bi-Fab' to 1100 microCi, respectively. At these very dose levels, no biochemical or histological evidence of renal damage was observed (kidney doses of <35 Gy). At equitoxic dosing, 213Bi-labeled Fab' fragments were significantly more effective than the respective 90Y-labeled conjugates. In the metastatic model, all untreated controls died from rapidly progressing hepatic metastases at 6-8 weeks after tumor inoculation, whereas a histologically confirmed cure was observed in 95% of those animals treated with 700 microCi of 213Bi-Fab' 10 days after model induction, which is in contrast to an only 20% cure rate in mice treated with 250 microCi of 90Y-Fab'. These data show that RIT with alpha emitters may be therapeutically more effective than conventional beta emitters. Surprisingly, maximum tolerated blood doses were, at 5-8 Gy, very similar between high-LET alpha and low-LET beta emitters. Due to its short physical half-life, 213Bi appears to be especially suitable for use in conjunction with fast-clearing fragments.  (+info)

Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments. (5/426)

We have been investigating the use of cross-linked divalent (DFM) and trivalent (TFM) versions of the anti-carcinoembryonic antigen (CEA) monoclonal antibody A5B7 as possible alternatives to the parent forms (IgG and F(ab')2) which have been used previously in clinical radioimmunotherapy (RIT) studies in colorectal carcinoma. Comparative biodistribution studies of similar sized DFM and F(ab')2 and TFM and IgG, radiolabelled with both 131I and 90Y have been described previously using the human colorectal tumour LS174T nude mouse xenograft model (Casey et al (1996) Br J Cancer 74: 1397-1405). In this study quantitative estimates of radiation distribution and RIT in the xenograft model provided more insight into selecting the most suitable combination for future RIT. Radiation doses were significantly higher in all tissues when antibodies were labelled with 90Y. Major contributing organs were the kidneys, liver and spleen. The extremely high absorbed dose to the kidneys on injection of 90Y-labelled DFM and F(ab')2 as a result of accumulation of the radiometal would result in extremely high toxicity. These combinations are clearly unsuitable for RIT. Cumulative dose of 90Y-TFM to the kidney was 3 times lower than the divalent forms but still twice as high as for 90Y-IgG. TFM clears faster from the blood than IgG, producing higher tumour to blood ratios. Therefore when considering only the tumour to blood ratios of the total absorbed dose, the data suggests that TFM would be the most suitable candidate. However, when corrected for equitoxic blood levels, doses to normal tissues for TFM were approximately twice the level of IgG, producing a two-fold increase in the overall tumour to normal tissue ratio. In addition RIT revealed that for a similar level of toxicity and half the administered activity, 90Y-IgG produced a greater therapeutic response. This suggests that the most promising A5B7 antibody form with the radionuclide 90Y may be IgG. Dosimetry analysis revealed that the tumour to normal tissue ratios were greater for all 131I-labelled antibodies. This suggests that 131I may be a more suitable radionuclide for RIT, in terms of lower toxicity to normal tissues. The highest tumour to blood dose and tumour to normal tissue ratio at equitoxic blood levels was 131I-labelled DFM, suggesting that 131I-DFM may be best combination of antibody and radionuclide for A5B7. The dosimetry estimates were in agreement with RIT results in that twice the activity of 131I-DFM must be administered to produce a similar therapeutic effect as 131I-TFM. The toxicity in this therapy experiment was minimal and further experiments at higher doses are required to observe if there would be any advantage of a higher initial dose rate for 131I-DFM.  (+info)

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. (6/426)

PURPOSE: Yttrium-90 ibritumomab tiuxetan (IDEC-Y2B8) is a murine immunoglobulin G1 kappa monoclonal antibody that covalently binds MX-DTPA (tiuxetan), which chelates the radioisotope yttrium-90. The antibody targets CD20, a B-lymphocyte antigen. A multicenter phase I/II trial was conducted to compare two doses of unlabeled rituximab given before radiolabeled antibody, to determine the maximum-tolerated single dose of IDEC-Y2B8 that could be administered without stem-cell support, and to evaluate safety and efficacy. PATIENTS AND METHODS: Eligible patients had relapsed or refractory (two prior regimens or anthracycline if low-grade disease) CD20(+) B-cell low-grade, intermediate-grade, or mantle-cell non-Hodgkin's lymphoma (NHL). There was no limit on bulky disease, and 59% had at least one mass > or = 5 cm. RESULTS: The maximum-tolerated dose was 0.4 mCi/kg IDEC-Y2B8 (0.3 mCi/kg for patients with baseline platelet counts 100 to 149,000/microL). The overall response rate for the intent-to-treat population (n = 51) was 67% (26% complete response [CR]; 41% partial response [PR]); for low-grade disease (n = 34), 82% (26% CR; 56% PR); for intermediate-grade disease (n = 14), 43%; and for mantle-cell disease (n = 3), 0%. Responses occurred in patients with bulky disease (> or = 7 cm; 41%) and splenomegaly (50%). Kaplan-Meier estimate of time to disease progression in responders and duration of response is 12.9+ months and 11.7+ months, respectively. Adverse events were primarily hematologic and correlated with baseline extent of marrow involvement with NHL and baseline platelet count. One patient (2%) developed an anti-antibody response (human antichimeric antibody/human antimouse antibody). CONCLUSION: These phase I/II data demonstrate that IDEC-Y2B8 radioimmunotherapy is a safe and effective alternative for outpatient therapy of patients with relapsed or refractory NHL. A phase III study is ongoing.  (+info)

Effects of intracoronary radiation on thrombosis after balloon overstretch injury in the porcine model. (7/426)

BACKGROUND: The main complications of PTCA remain thrombosis and restenosis. Recent studies have demonstrated reduction in the neointimal hyperplasia after intracoronary radiation (IR) with doses of 10 to 25 Gy of ionizing radiation delivered by either beta- or gamma-emitters to injured vessels. The purpose of this study was to examine the effect of ionizing radiation on the thrombosis rate (TR) of injured porcine coronary arteries. METHODS AND RESULTS: Thirty-four juvenile swine (63 coronary arteries) were subjected to overstretch balloon injury followed by IR with doses of 0 to 18 Gy of either beta- or gamma-radiation. Two weeks after treatment, tissue sections were perfusion-fixed, stained with hematoxylin-eosin and Verhoeff-van Gieson's stain, and analyzed for presence of a thrombus, thrombus morphology, and neointima formation by computer-assisted histomorphometry techniques. Although the overall TR increased dose-dependently from 0 to 18 Gy prescribed dose, luminal thrombi decreased. Thrombus area also decreased with increasing radiation dose, whether assessed at the prescription point or at the luminal surface, which corresponded to decreased intimal area. Furthermore, luminal thrombi present after IR tended to consist mostly of fibrin and thus were less organized than in controls. CONCLUSIONS: These results suggest that IR induces thrombosis but does not necessarily compromise the lumen. Strategies for reducing TR may further decrease intimal area as well as increasing the safety of this therapy.  (+info)

Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. (8/426)

Pretargeted radioimmunotherapy (PRIT) was evaluated using an antibody-streptavidin conjugate, followed by a biotin-galactose-human serum albumin clearing agent and 90Y-dodecane tetraacetic acid (DOTA)-biotin as the final step for therapy. The objective was to develop a clinical protocol that could show an improved tumor-to-red marrow therapeutic ratio compared with conventional radioimmunotherapy (RIT) and at the same time preserve the efficiency of tumor targeting. METHOD: Forty-three patients with adenocarcinomas reactive to NR-LU-10 murine monoclonal antibody received the 3 components. Doses and timing parameters were varied to develop an optimized schema. In some patients, the conjugate was radiolabeled with 186Re as an imaging tracer to assess biodistribution of the conjugate and effectiveness of the clearing agent. 111In-DOTA-biotin was coinjected with 90Y-DOTA-biotin for quantitative imaging. Safety, biodistribution, pharmacokinetics, dosimetry, and antiglobulin formation were evaluated. RESULTS: The optimal schema was defined as a conjugate dose of 125 microg/mL plasma volume followed at 48 h by a clearing agent in a 10:1 molar ratio of clearing agent to serum conjugate. The therapeutic third step was 0.5 mg radiobiotin administered 24 h later. No significant adverse events were observed after administration of any of the components. The mean tumor-to-marrow absorbed dose ratio when using the optimized PRIT schema was 63:1, compared with a 6:1 ratio reported previously for conventional RIT. Antiglobulin to murine antibody and to streptavidin developed in most patients. CONCLUSION: This initial study confirmed that the PRIT approach is safe and feasible and achieved a higher therapeutic ratio than that achieved with conventional RIT using the same antibody.  (+info)

Yttrium is not a medical term itself, but it is a chemical element with the symbol "Y" and atomic number 39. It is a silvery-metallic transition element that is found in rare earth minerals.

In the field of medicine, yttrium is used in the production of some medical devices and treatments. For example, yttrium-90 is a radioactive isotope that is used in the treatment of certain types of cancer, such as liver cancer and lymphoma. Yttrium-90 is often combined with other substances to form tiny beads or particles that can be injected directly into tumors, where they release radiation that helps to destroy cancer cells.

Yttrium aluminum garnet (YAG) lasers are also used in medical procedures such as eye surgery and dental work. These lasers emit a highly concentrated beam of light that can be used to cut or coagulate tissue with great precision.

Overall, while yttrium is not a medical term itself, it does have important applications in the field of medicine.

Yttrium radioisotopes are radioactive isotopes or variants of the element Yttrium, which is a rare earth metal. These radioisotopes are artificially produced and have unstable nuclei that emit radiation in the form of gamma rays or high-speed particles. Examples of yttrium radioisotopes include Yttrium-90 and Yttrium-86, which are used in medical applications such as radiotherapy for cancer treatment and molecular imaging for diagnostic purposes.

Yttrium-90 is a pure beta emitter with a half-life of 64.1 hours, making it useful for targeted radionuclide therapy. It can be used to treat liver tumors, leukemia, and lymphoma by attaching it to monoclonal antibodies or other targeting agents that selectively bind to cancer cells.

Yttrium-86 is a positron emitter with a half-life of 14.7 hours, making it useful for positron emission tomography (PET) imaging. It can be used to label radiopharmaceuticals and track their distribution in the body, providing information on the location and extent of disease.

It is important to note that handling and use of radioisotopes require specialized training and equipment due to their potential radiation hazards.

Yttrium isotopes are different forms of the element yttrium, which have the same number of protons in their atomic nuclei (which is 39 and defines the element), but different numbers of neutrons. This results in a difference in the mass number of the isotopes. For example, the most common yttrium isotope is Y-89, which has 39 protons and 50 neutrons, giving it a mass number of 89. However, there are also other yttrium isotopes such as Y-88, Y-90, Y-91 etc., with different numbers of neutrons and thus different mass numbers. Some yttrium isotopes are stable, while others are unstable and radioactive, meaning they will decay into other elements over time.

Radioisotopes, also known as radioactive isotopes or radionuclides, are variants of chemical elements that have unstable nuclei and emit radiation in the form of alpha particles, beta particles, gamma rays, or conversion electrons. These isotopes are formed when an element's nucleus undergoes natural or artificial radioactive decay.

Radioisotopes can be produced through various processes, including nuclear fission, nuclear fusion, and particle bombardment in a cyclotron or other types of particle accelerators. They have a wide range of applications in medicine, industry, agriculture, research, and energy production. In the medical field, radioisotopes are used for diagnostic imaging, radiation therapy, and in the labeling of molecules for research purposes.

It is important to note that handling and using radioisotopes requires proper training, safety measures, and regulatory compliance due to their ionizing radiation properties, which can pose potential health risks if not handled correctly.

I'm sorry for any confusion, but "Neodymium" is not a medical term. It is a chemical element with the symbol Nd and atomic number 60. Neodymium is a rare-earth metal that has been used in various industrial and technological applications, such as magnets, lasers, and glass coloration. It is not directly related to medical terminology or healthcare.

Solid-state lasers are a type of laser that uses solid materials as the gain medium – the material that amplifies the light energy to produce laser emissions. In contrast to gas or liquid lasers, solid-state lasers use a crystal, ceramic, or glass as the gain medium. The active laser medium in solid-state lasers is typically doped with rare earth ions, such as neodymium (Nd), yttrium (Y), erbium (Er), or thulium (Tm).

The most common type of solid-state laser is the neodymium-doped yttrium aluminum garnet (Nd:YAG) laser. In this laser, neodymium ions are doped into a crystal lattice made up of yttrium, aluminum, and garnet (YAG). The Nd:YAG laser emits light at a wavelength of 1064 nanometers (nm), which can be frequency-doubled to produce emissions at 532 nm.

Solid-state lasers have several advantages over other types of lasers, including high efficiency, long lifetimes, and compact size. They are widely used in various applications, such as material processing, medical treatments, scientific research, and military technology.

Zinc radioisotopes are unstable isotopes or variants of the element zinc that undergo radioactive decay, emitting radiation in the process. These isotopes have a different number of neutrons than the stable isotope of zinc (zinc-64), which contributes to their instability and tendency to decay.

Examples of zinc radioisotopes include zinc-65, zinc-70, and zinc-72. These isotopes are often used in medical research and diagnostic procedures due to their ability to emit gamma rays or positrons, which can be detected using specialized equipment.

Zinc radioisotopes may be used as tracers to study the metabolism and distribution of zinc in the body, or as therapeutic agents to deliver targeted radiation therapy to cancer cells. However, it is important to note that the use of radioisotopes carries potential risks, including exposure to ionizing radiation and the potential for damage to healthy tissues.

Laser therapy, also known as phototherapy or laser photobiomodulation, is a medical treatment that uses low-intensity lasers or light-emitting diodes (LEDs) to stimulate healing, reduce pain, and decrease inflammation. It works by promoting the increase of cellular metabolism, blood flow, and tissue regeneration through the process of photobiomodulation.

The therapy can be used on patients suffering from a variety of acute and chronic conditions, including musculoskeletal injuries, arthritis, neuropathic pain, and wound healing complications. The wavelength and intensity of the laser light are precisely controlled to ensure a safe and effective treatment.

During the procedure, the laser or LED device is placed directly on the skin over the area of injury or discomfort. The non-ionizing light penetrates the tissue without causing heat or damage, interacting with chromophores in the cells to initiate a series of photochemical reactions. This results in increased ATP production, modulation of reactive oxygen species, and activation of transcription factors that lead to improved cellular function and reduced pain.

In summary, laser therapy is a non-invasive, drug-free treatment option for various medical conditions, providing patients with an alternative or complementary approach to traditional therapies.

Radioimmunotherapy (RIT) is a medical treatment that combines the specificity of antibodies and the therapeutic effects of radiation to target and destroy cancer cells. It involves the use of radioactive isotopes, which are attached to monoclonal antibodies, that recognize and bind to antigens expressed on the surface of cancer cells. Once bound, the radioactivity emitted from the isotope irradiates the cancer cells, causing damage to their DNA and leading to cell death. This targeted approach helps minimize radiation exposure to healthy tissues and reduces side effects compared to conventional radiotherapy techniques. RIT has been used in the treatment of various hematological malignancies, such as non-Hodgkin lymphoma, and is being investigated for solid tumors as well.

Indium radioisotopes refer to specific types of radioactive indium atoms, which are unstable and emit radiation as they decay. Indium is a chemical element with the symbol In and atomic number 49. Its radioisotopes are often used in medical imaging and therapy due to their unique properties.

For instance, one commonly used indium radioisotope is Indium-111 (^111In), which has a half-life of approximately 2.8 days. It emits gamma rays, making it useful for diagnostic imaging techniques such as single-photon emission computed tomography (SPECT). In clinical applications, indium-111 is often attached to specific molecules or antibodies that target particular cells or tissues in the body, allowing medical professionals to monitor biological processes and identify diseases like cancer.

Another example is Indium-113m (^113mIn), which has a half-life of about 99 minutes. It emits low-energy gamma rays and is used as a source for in vivo counting, typically in the form of indium chloride (InCl3) solution. This radioisotope can be used to measure blood flow, ventilation, and other physiological parameters.

It's important to note that handling and using radioisotopes require proper training and safety measures due to their ionizing radiation properties.

"Light coagulation," also known as "laser coagulation," is a medical term that refers to the use of laser technology to cauterize (seal or close) tissue. This procedure uses heat generated by a laser to cut, coagulate, or destroy tissue. In light coagulation, the laser beam is focused on the blood vessels in question, causing the blood within them to clot and the vessels to seal. This can be used for various medical purposes, such as stopping bleeding during surgery, destroying abnormal tissues (like tumors), or treating eye conditions like diabetic retinopathy and age-related macular degeneration.

It's important to note that this is a general definition, and the specific use of light coagulation may vary depending on the medical specialty and the individual patient's needs. As always, it's best to consult with a healthcare professional for more detailed information about any medical procedure or treatment.

Erbium is a chemical element with the symbol "Er" and atomic number 68. It is a rare earth element that belongs to the lanthanide series in the periodic table. Erbium is not naturally found in its pure form, but it is typically extracted from minerals such as xenotime and bastnasite.

In medical terms, erbium is used in the form of erbium-doped yttrium aluminum garnet (Er:YAG) lasers for various surgical procedures. These lasers emit light at a wavelength of 2940 nanometers, which is highly absorbed by water and therefore ideal for cutting and coagulating tissue with minimal thermal damage to surrounding tissues. Erbium lasers are commonly used in dermatology and ophthalmology for procedures such as skin resurfacing, removal of tattoos and birthmarks, and cataract surgery.

The Radioisotope Dilution Technique is a method used in nuclear medicine to measure the volume and flow rate of a particular fluid in the body. It involves introducing a known amount of a radioactive isotope, or radioisotope, into the fluid, such as blood. The isotope mixes with the fluid, and samples are then taken from the fluid at various time points.

By measuring the concentration of the radioisotope in each sample, it is possible to calculate the total volume of the fluid based on the amount of the isotope introduced and the dilution factor. The flow rate can also be calculated by measuring the concentration of the isotope over time and using the formula:

Flow rate = Volume/Time

This technique is commonly used in medical research and clinical settings to measure cardiac output, cerebral blood flow, and renal function, among other applications. It is a safe and reliable method that has been widely used for many years. However, it does require the use of radioactive materials and specialized equipment, so it should only be performed by trained medical professionals in appropriate facilities.

Intra-articular injections refer to the administration of medication directly into a joint space. This route of administration is used for treating various joint conditions such as inflammation, pain, and arthritis. Commonly injected medications include corticosteroids, local anesthetics, and viscosupplementation agents. The procedure is usually performed using imaging guidance, like ultrasound or fluoroscopy, to ensure accurate placement of the medication within the joint.

A posterior capsulotomy is a surgical procedure that involves making an opening in the back part (posterior) of the lens capsule, which is a thin, clear membrane that holds the lens in place inside the eye. This procedure is typically performed to treat after-cataract, also known as posterior capsular opacification (PCO), which can cause vision loss or disturbance after cataract surgery. During cataract surgery, the cloudy natural lens of the eye is removed and replaced with an artificial intraocular lens (IOL). However, sometimes the back part of the lens capsule may become hazy or opaque over time, leading to visual symptoms similar to those experienced before cataract surgery.

In a posterior capsulotomy, a laser (usually a YAG laser) is used to create an opening in the cloudy posterior capsule, allowing light to pass through and restoring clear vision. The procedure is typically quick, painless, and performed as an outpatient procedure in a doctor's office or clinic. Patients may experience some side effects such as floaters, glare, or flashes of light after the procedure, but these usually resolve within a few days or weeks.

I'm sorry for any confusion, but "Ytterbium" is not a medical term. It is a chemical element with the symbol "Yb" and atomic number 70. Ytterbium is a rare earth metal that is silvery white, soft, malleable, and has many uses in scientific research, particularly in the field of laser technology.

If you have any medical questions or terms you would like me to define, please let me know!

Strontium radioisotopes are radioactive isotopes of the element strontium. Strontium is an alkaline earth metal that is found in nature and has several isotopes, some of which are stable and some of which are radioactive. The radioactive isotopes of strontium, also known as strontium radionuclides, decay and emit radiation in the form of beta particles.

Strontium-89 (^89Sr) and strontium-90 (^90Sr) are two common radioisotopes of strontium that are used in medical applications. Strontium-89 is a pure beta emitter with a half-life of 50.5 days, which makes it useful for the treatment of bone pain associated with metastatic cancer. When administered, strontium-89 is taken up by bones and irradiates the bone tissue, reducing pain and improving quality of life in some patients.

Strontium-90, on the other hand, has a longer half-life of 28.8 years and emits more powerful beta particles than strontium-89. It is used as a component in radioactive waste and in some nuclear weapons, but it is not used in medical applications due to its long half-life and high radiation dose.

It's important to note that exposure to strontium radioisotopes can be harmful to human health, especially if ingested or inhaled. Therefore, handling and disposal of strontium radioisotopes require special precautions and regulations.

Iodine radioisotopes are radioactive isotopes of the element iodine, which decays and emits radiation in the form of gamma rays. Some commonly used iodine radioisotopes include I-123, I-125, I-131. These radioisotopes have various medical applications such as in diagnostic imaging, therapy for thyroid disorders, and cancer treatment.

For example, I-131 is commonly used to treat hyperthyroidism and differentiated thyroid cancer due to its ability to destroy thyroid tissue. On the other hand, I-123 is often used in nuclear medicine scans of the thyroid gland because it emits gamma rays that can be detected by a gamma camera, allowing for detailed images of the gland's structure and function.

It is important to note that handling and administering radioisotopes require specialized training and safety precautions due to their radiation-emitting properties.

Rare earth metals, also known as rare earth elements, are a group of 17 metallic elements found in the periodic table. They include:

1. Lanthanum (La)
2. Cerium (Ce)
3. Praseodymium (Pr)
4. Neodymium (Nd)
5. Promethium (Pm)
6. Samarium (Sm)
7. Europium (Eu)
8. Gadolinium (Gd)
9. Terbium (Tb)
10. Dysprosium (Dy)
11. Holmium (Ho)
12. Erbium (Er)
13. Thulium (Tm)
14. Ytterbium (Yb)
15. Lutetium (Lu)
1

Krypton is a noble gas with the symbol Kr and atomic number 36. It exists in various radioisotopes, which are unstable isotopes of krypton that undergo radioactive decay. A few examples include:

1. Krypton-81: This radioisotope has a half-life of about 2.1 x 10^5 years and decays via electron capture to rubidium-81. It is produced naturally in the atmosphere by cosmic rays.
2. Krypton-83: With a half-life of approximately 85.7 days, this radioisotope decays via beta decay to bromine-83. It can be used in medical imaging for lung ventilation studies.
3. Krypton-85: This radioisotope has a half-life of about 10.7 years and decays via beta decay to rubidium-85. It is produced as a byproduct of nuclear fission and can be found in trace amounts in the atmosphere.
4. Krypton-87: With a half-life of approximately 76.3 minutes, this radioisotope decays via beta decay to rubidium-87. It is not found naturally on Earth but can be produced artificially.

It's important to note that while krypton radioisotopes have medical applications, they are also associated with potential health risks due to their radioactivity. Proper handling and safety precautions must be taken when working with these substances.

I'm sorry for any confusion, but "Scandium" is not a medical term. It is a chemical element with the symbol Sc and atomic number 21. It is a silvery-white metal that is soft, workable, and highly resistant to corrosion. In medicine, scandium and its compounds are not used in therapy or diagnosis.

Sodium radioisotopes are unstable forms of sodium, an element naturally occurring in the human body, that emit radiation as they decay over time. These isotopes can be used for medical purposes such as imaging and treatment of various diseases. Commonly used sodium radioisotopes include Sodium-22 (^22Na) and Sodium-24 (^24Na).

It's important to note that the use of radioisotopes in medicine should be under the supervision of trained medical professionals, as improper handling or exposure can pose health risks.

Radioactivity is not typically considered within the realm of medical definitions, but since it does have medical applications and implications, here is a brief explanation:

Radioactivity is a natural property of certain elements (referred to as radioisotopes) that emit particles or electromagnetic waves due to changes in their atomic nuclei. This process can occur spontaneously without any external influence, leading to the emission of alpha particles, beta particles, gamma rays, or neutrons. These emissions can penetrate various materials and ionize atoms along their path, which can cause damage to living tissues.

In a medical context, radioactivity is used in both diagnostic and therapeutic settings:

1. Diagnostic applications include imaging techniques such as positron emission tomography (PET) scans and single-photon emission computed tomography (SPECT), where radioisotopes are introduced into the body to visualize organ function or detect diseases like cancer.
2. Therapeutic uses involve targeting radioisotopes directly at cancer cells, either through external beam radiation therapy or internal radiotherapy, such as brachytherapy, where a radioactive source is placed near or within the tumor.

While radioactivity has significant medical benefits, it also poses risks due to ionizing radiation exposure. Proper handling and safety measures are essential when working with radioactive materials to minimize potential harm.

Barium radioisotopes are radioactive forms of the element barium, which are used in medical imaging procedures to help diagnose various conditions. The radioisotopes emit gamma rays that can be detected by external devices, allowing doctors to visualize the inside of the body. Barium sulfate is often used as a contrast agent in X-rays and CT scans, but when combined with a radioisotope such as barium-133, barium-198, or barium-207, it can provide more detailed images of specific organs or systems.

For example, barium sulfate mixed with barium-133 may be used in a lung scan to help diagnose pulmonary embolism or other respiratory conditions. Barium-207 is sometimes used in bone scans to detect fractures, tumors, or infections.

It's important to note that the use of radioisotopes carries some risks, including exposure to radiation and potential allergic reactions to the barium compound. However, these risks are generally considered low compared to the benefits of accurate diagnosis and effective treatment.

Radionuclide imaging, also known as nuclear medicine, is a medical imaging technique that uses small amounts of radioactive material, called radionuclides or radiopharmaceuticals, to diagnose and treat various diseases and conditions. The radionuclides are introduced into the body through injection, inhalation, or ingestion and accumulate in specific organs or tissues. A special camera then detects the gamma rays emitted by these radionuclides and converts them into images that provide information about the structure and function of the organ or tissue being studied.

Radionuclide imaging can be used to evaluate a wide range of medical conditions, including heart disease, cancer, neurological disorders, gastrointestinal disorders, and bone diseases. The technique is non-invasive and generally safe, with minimal exposure to radiation. However, it should only be performed by qualified healthcare professionals in accordance with established guidelines and regulations.

Tin radioisotopes refer to specific variants of the element tin that have unstable nuclei and emit radiation as they decay towards a more stable state. These isotopes are often produced in nuclear reactors or particle accelerators and can be used in a variety of medical applications, such as:

1. Medical Imaging: Tin-117m, for example, is used as a radiopharmaceutical in medical imaging studies to help diagnose various conditions, including bone disorders and liver diseases.
2. Radiation Therapy: Tin-125 can be used in the treatment of certain types of cancer, such as prostate cancer, through brachytherapy - a type of radiation therapy that involves placing a radioactive source directly into or near the tumor.
3. Radioisotope Production: Tin-106 is used as a parent isotope in the production of other medical radioisotopes, such as iodine-125 and gallium-67.

It's important to note that handling and using radioisotopes requires specialized training and equipment due to their potential radiation hazards.

Zirconium is not a medical term, but it is a chemical element with the symbol Zr and atomic number 40. It is a gray-white, strong, corrosion-resistant transition metal that is used primarily in nuclear reactors, as an opacifier in glazes for ceramic cookware, and in surgical implants such as artificial joints due to its biocompatibility.

In the context of medical devices or implants, zirconium alloys may be used for their mechanical properties and resistance to corrosion. For example, zirconia (a form of zirconium dioxide) is a popular material for dental crowns and implants due to its durability, strength, and natural appearance.

However, it's important to note that while zirconium itself is not considered a medical term, there are various medical applications and devices that utilize zirconium-based materials.

Carbon radioisotopes are radioactive isotopes of carbon, which is an naturally occurring chemical element with the atomic number 6. The most common and stable isotope of carbon is carbon-12 (^12C), but there are also several radioactive isotopes, including carbon-11 (^11C), carbon-14 (^14C), and carbon-13 (^13C). These radioisotopes have different numbers of neutrons in their nuclei, which makes them unstable and causes them to emit radiation.

Carbon-11 has a half-life of about 20 minutes and is used in medical imaging techniques such as positron emission tomography (PET) scans. It is produced by bombarding nitrogen-14 with protons in a cyclotron.

Carbon-14, also known as radiocarbon, has a half-life of about 5730 years and is used in archaeology and geology to date organic materials. It is produced naturally in the atmosphere by cosmic rays.

Carbon-13 is stable and has a natural abundance of about 1.1% in carbon. It is not radioactive, but it can be used as a tracer in medical research and in the study of metabolic processes.

"Iron radioisotopes" refer to specific forms of the element iron that have unstable nuclei and emit radiation. These isotopes are often used in medical imaging and treatment procedures due to their ability to be detected by specialized equipment. Common iron radioisotopes include Iron-52, Iron-55, Iron-59, and Iron-60. They can be used as tracers to study the distribution, metabolism, or excretion of iron in the body, or for targeted radiation therapy in conditions such as cancer.

Brachytherapy is a type of cancer treatment that involves placing radioactive material directly into or near the tumor site. The term "brachy" comes from the Greek word for "short," which refers to the short distance that the radiation travels. This allows for a high dose of radiation to be delivered directly to the tumor while minimizing exposure to healthy surrounding tissue.

There are two main types of brachytherapy:

1. Intracavitary brachytherapy: The radioactive material is placed inside a body cavity, such as the uterus or windpipe.
2. Interstitial brachytherapy: The radioactive material is placed directly into the tumor or surrounding tissue using needles, seeds, or catheters.

Brachytherapy can be used alone or in combination with other cancer treatments such as surgery, external beam radiation therapy, and chemotherapy. It may be recommended for a variety of cancers, including prostate, cervical, vaginal, vulvar, head and neck, and skin cancers. The specific type of brachytherapy used will depend on the size, location, and stage of the tumor.

The advantages of brachytherapy include its ability to deliver a high dose of radiation directly to the tumor while minimizing exposure to healthy tissue, which can result in fewer side effects compared to other forms of radiation therapy. Additionally, brachytherapy is often a shorter treatment course than external beam radiation therapy, with some treatments lasting only a few minutes or hours.

However, there are also potential risks and side effects associated with brachytherapy, including damage to nearby organs and tissues, bleeding, infection, and pain. Patients should discuss the benefits and risks of brachytherapy with their healthcare provider to determine if it is an appropriate treatment option for them.

Copper radioisotopes are radioactive isotopes or variants of the chemical element copper. These isotopes have an unstable nucleus and emit radiation as they decay over time. Copper has several radioisotopes, including copper-64, copper-67, and copper-60, among others. These radioisotopes are used in various medical applications such as diagnostic imaging, therapy, and research. For example, copper-64 is used in positron emission tomography (PET) scans to help diagnose diseases like cancer, while copper-67 is used in targeted radionuclide therapy for cancer treatment. The use of radioisotopes in medicine requires careful handling and regulation due to their radiation hazards.

Phosphorus radioisotopes are radioactive isotopes or variants of the element phosphorus that emit radiation. Phosphorus has several radioisotopes, with the most common ones being phosphorus-32 (^32P) and phosphorus-33 (^33P). These radioisotopes are used in various medical applications such as cancer treatment and diagnostic procedures.

Phosphorus-32 has a half-life of approximately 14.3 days and emits beta particles, making it useful for treating certain types of cancer, such as leukemia and lymphoma. It can also be used in brachytherapy, a type of radiation therapy that involves placing a radioactive source close to the tumor.

Phosphorus-33 has a shorter half-life of approximately 25.4 days and emits both beta particles and gamma rays. This makes it useful for diagnostic procedures, such as positron emission tomography (PET) scans, where the gamma rays can be detected and used to create images of the body's internal structures.

It is important to note that handling and using radioisotopes requires specialized training and equipment to ensure safety and prevent radiation exposure.

Beta particles, also known as beta rays, are a type of ionizing radiation that consist of high-energy electrons or positrons emitted from the nucleus of certain radioactive isotopes during their decay process. When a neutron in the nucleus decays into a proton, it results in an excess energy state and one electron is ejected from the atom at high speed. This ejected electron is referred to as a beta particle.

Beta particles can have both positive and negative charges, depending on the type of decay process. Negative beta particles (β−) are equivalent to electrons, while positive beta particles (β+) are equivalent to positrons. They possess kinetic energy that varies in range, with higher energies associated with greater penetrating power.

Beta particles can cause ionization and excitation of atoms and molecules they encounter, leading to chemical reactions and potential damage to living tissues. Therefore, appropriate safety measures must be taken when handling materials that emit beta radiation.

A laser is not a medical term per se, but a physical concept that has important applications in medicine. The term "LASER" stands for "Light Amplification by Stimulated Emission of Radiation." It refers to a device that produces and amplifies light with specific characteristics, such as monochromaticity (single wavelength), coherence (all waves moving in the same direction), and high intensity.

In medicine, lasers are used for various therapeutic and diagnostic purposes, including surgery, dermatology, ophthalmology, and dentistry. They can be used to cut, coagulate, or vaporize tissues with great precision, minimizing damage to surrounding structures. Additionally, lasers can be used to detect and measure physiological parameters, such as blood flow and oxygen saturation.

It's important to note that while lasers are powerful tools in medicine, they must be used by trained professionals to ensure safe and effective treatment.

The knee joint, also known as the tibiofemoral joint, is the largest and one of the most complex joints in the human body. It is a synovial joint that connects the thighbone (femur) to the shinbone (tibia). The patella (kneecap), which is a sesamoid bone, is located in front of the knee joint and helps in the extension of the leg.

The knee joint is made up of three articulations: the femorotibial joint between the femur and tibia, the femoropatellar joint between the femur and patella, and the tibiofibular joint between the tibia and fibula. These articulations are surrounded by a fibrous capsule that encloses the synovial membrane, which secretes synovial fluid to lubricate the joint.

The knee joint is stabilized by several ligaments, including the medial and lateral collateral ligaments, which provide stability to the sides of the joint, and the anterior and posterior cruciate ligaments, which prevent excessive forward and backward movement of the tibia relative to the femur. The menisci, which are C-shaped fibrocartilaginous structures located between the femoral condyles and tibial plateaus, also help to stabilize the joint by absorbing shock and distributing weight evenly across the articular surfaces.

The knee joint allows for flexion, extension, and a small amount of rotation, making it essential for activities such as walking, running, jumping, and sitting.

Technetium is not a medical term itself, but it is a chemical element with the symbol Tc and atomic number 43. However, in the field of nuclear medicine, which is a branch of medicine that uses small amounts of radioactive material to diagnose or treat diseases, Technetium-99m (a radioisotope of technetium) is commonly used for various diagnostic procedures.

Technetium-99m is a metastable nuclear isomer of technetium-99, and it emits gamma rays that can be detected outside the body to create images of internal organs or tissues. It has a short half-life of about 6 hours, which makes it ideal for diagnostic imaging since it decays quickly and reduces the patient's exposure to radiation.

Technetium-99m is used in a variety of medical procedures, such as bone scans, lung scans, heart scans, liver-spleen scans, brain scans, and kidney scans, among others. It can be attached to different pharmaceuticals or molecules that target specific organs or tissues, allowing healthcare professionals to assess their function or identify any abnormalities.

Mercury radioisotopes refer to specific variants of the element mercury that have unstable nuclei and emit radiation as they decay towards a more stable state. These isotopes are often produced in nuclear reactors or particle accelerators for various medical, industrial, and research applications. In the medical field, mercury-203 (^203Hg) and mercury-207 (^207Hg) are used as gamma emitters in diagnostic procedures and therapeutic treatments. However, due to environmental and health concerns associated with mercury, its use in medical applications has significantly decreased over time.

Technetium Tc 99m Sulfur Colloid is a radioactive tracer used in medical imaging procedures, specifically in nuclear medicine. It is composed of tiny particles of sulfur colloid that are labeled with the radioisotope Technetium-99m. This compound is typically injected into the patient's body, where it accumulates in certain organs or tissues, depending on the specific medical test being conducted.

The radioactive emissions from Technetium Tc 99m Sulfur Colloid are then detected by a gamma camera, which produces images that can help doctors diagnose various medical conditions, such as liver disease, inflammation, or tumors. The half-life of Technetium-99m is approximately six hours, which means that its radioactivity decreases rapidly and is eliminated from the body within a few days.

Cesium is a chemical element with the atomic number 55 and the symbol Cs. There are several isotopes of cesium, which are variants of the element that have different numbers of neutrons in their nuclei. The most stable and naturally occurring cesium isotope is cesium-133, which has 78 neutrons and a half-life of more than 3 x 10^20 years (effectively stable).

However, there are also radioactive isotopes of cesium, including cesium-134 and cesium-137. Cesium-134 has a half-life of about 2 years, while cesium-137 has a half-life of about 30 years. These isotopes are produced naturally in trace amounts by the decay of uranium and thorium in the Earth's crust, but they can also be produced artificially in nuclear reactors and nuclear weapons tests.

Cesium isotopes are commonly used in medical research and industrial applications. For example, cesium-137 is used as a radiation source in cancer therapy and industrial radiography. However, exposure to high levels of radioactive cesium can be harmful to human health, causing symptoms such as nausea, vomiting, diarrhea, and potentially more serious effects such as damage to the central nervous system and an increased risk of cancer.

Cerium is a naturally occurring element found in the Earth's crust, and it has several radioisotopes, which are radioactive isotopes or forms of cerium. These isotopes have unstable nuclei that emit radiation as they decay into more stable forms. Here are some examples of cerium radioisotopes:

* Cerium-134: This radioisotope has a half-life of about 3.12 days, which means that half of its atoms will decay into other elements in this time period. It decays by emitting beta particles and gamma rays.
* Cerium-137: This is a long-lived radioisotope with a half-life of about 2.5 years. It decays by emitting beta particles and gamma rays, and it can be used in medical imaging and cancer treatment. However, if released into the environment, it can pose a radiation hazard to humans and other organisms.
* Cerium-141: This radioisotope has a half-life of about 32.5 days, and it decays by emitting beta particles and gamma rays. It is produced in nuclear reactors and can be used for research purposes.
* Cerium-144: This radioisotope has a half-life of about 284 days, and it decays by emitting beta particles and gamma rays. It is produced in nuclear reactors and can be used for research purposes.

It's important to note that handling and working with radioisotopes requires proper training and protective measures to ensure safety and prevent radiation exposure.

Cobalt isotopes are variants of the chemical element Cobalt (Co) that have different numbers of neutrons in their atomic nuclei. This results in the different isotopes having slightly different masses and varying levels of stability.

The most naturally occurring stable cobalt isotope is Co-59, which contains 27 neutrons in its nucleus. However, there are also several radioactive isotopes of cobalt, including Co-60, which is a commonly used medical and industrial radioisotope.

Co-60 has 30 neutrons in its nucleus and undergoes beta decay, emitting gamma rays and becoming Nickel-60. It has a half-life of approximately 5.27 years, making it useful for a variety of applications, including cancer treatment, industrial radiography, and sterilization of medical equipment.

Other radioactive isotopes of cobalt include Co-57, which has a half-life of 271.8 days and is used in medical imaging, and Co-56, which has a half-life of just 77.2 seconds and is used in research.

I'm sorry for any confusion, but Hafnium is not a medical term. It is a chemical element with the symbol Hf and atomic number 72. Hafnium is a lustrous, silvery, tetravalent transition metal that chemically resembles zirconium and is found in zirconium minerals.

It has no relevance to medical terminology or healthcare. If you have any questions related to medical definitions or health-related topics, I'd be happy to try to help with those instead!

Gold radioisotopes are unstable forms of gold that emit radiation as they decay into more stable elements. They are not typically used for medical purposes, but there have been some experimental uses in the treatment of cancer. For example, Gold-198 is a radioisotope that has been used in the brachytherapy (internal radiation therapy) of certain types of tumors. It releases high-energy gamma rays and is often used as a sealed source for the treatment of cancer.

It's important to note that the use of radioisotopes in medicine, including gold radioisotopes, should only be performed under the supervision of trained medical professionals and radiation safety experts due to the potential risks associated with radiation exposure.

Isotope labeling is a scientific technique used in the field of medicine, particularly in molecular biology, chemistry, and pharmacology. It involves replacing one or more atoms in a molecule with a radioactive or stable isotope of the same element. This modified molecule can then be traced and analyzed to study its structure, function, metabolism, or interaction with other molecules within biological systems.

Radioisotope labeling uses unstable radioactive isotopes that emit radiation, allowing for detection and quantification of the labeled molecule using various imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT). This approach is particularly useful in tracking the distribution and metabolism of drugs, hormones, or other biomolecules in living organisms.

Stable isotope labeling, on the other hand, employs non-radioactive isotopes that do not emit radiation. These isotopes have different atomic masses compared to their natural counterparts and can be detected using mass spectrometry. Stable isotope labeling is often used in metabolic studies, protein turnover analysis, or for identifying the origin of specific molecules within complex biological samples.

In summary, isotope labeling is a versatile tool in medical research that enables researchers to investigate various aspects of molecular behavior and interactions within biological systems.

Lead radioisotopes refer to specific types of radioactive isotopes (or radionuclides) of the element lead. These isotopes have unstable nuclei and emit radiation as they decay over time, changing into different elements in the process. Examples of lead radioisotopes include lead-210, lead-212, and lead-214. These isotopes are often found in the decay chains of heavier radioactive elements such as uranium and thorium, and they have various applications in fields like nuclear medicine, research, and industrial radiography. However, exposure to high levels of radiation from lead radioisotopes can pose significant health risks, including damage to DNA and increased risk of cancer.

Diagnostic techniques using radioisotopes, also known as nuclear medicine, are medical diagnostic procedures that use small amounts of radioactive material, called radioisotopes or radionuclides, to diagnose and monitor various diseases and conditions. The radioisotopes are introduced into the body through different routes (such as injection, inhalation, or ingestion) and accumulate in specific organs or tissues.

The gamma rays or photons emitted by these radioisotopes are then detected by specialized imaging devices, such as gamma cameras or PET scanners, which generate images that provide information about the structure and function of the organ or tissue being examined. This information helps healthcare professionals to make accurate diagnoses, monitor disease progression, assess treatment response, and plan appropriate therapies.

Common diagnostic techniques using radioisotopes include:

1. Radionuclide imaging (also known as scintigraphy): A gamma camera is used to produce images of specific organs or tissues after the administration of a radioisotope. Examples include bone scans, lung scans, heart scans, and brain scans.
2. Positron emission tomography (PET) scans: A PET scanner detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide, such as fluorodeoxyglucose (FDG), which is often used in oncology to assess metabolic activity and identify cancerous lesions.
3. Single-photon emission computed tomography (SPECT): A specialized gamma camera rotates around the patient, acquiring multiple images from different angles that are then reconstructed into a 3D image, providing detailed information about organ function and structure.

Diagnostic techniques using radioisotopes offer several advantages, including high sensitivity, non-invasiveness, and the ability to assess both anatomical and functional aspects of organs and tissues. However, they also involve exposure to ionizing radiation, so their use should be balanced against potential risks and benefits, and alternative diagnostic methods should be considered when appropriate.

Zinc isotopes refer to variants of the chemical element zinc, each with a different number of neutrons in their atomic nucleus. Zinc has five stable isotopes: zinc-64, zinc-66, zinc-67, zinc-68, and zinc-70. These isotopes have naturally occurring abundances that vary, with zinc-64 being the most abundant at approximately 48.6%.

Additionally, there are also several radioactive isotopes of zinc, including zinc-65, zinc-71, and zinc-72, among others. These isotopes have unstable nuclei that decay over time, emitting radiation in the process. They are not found naturally on Earth and must be produced artificially through nuclear reactions.

Medical Definition: Zinc isotopes refer to variants of the chemical element zinc with different numbers of neutrons in their atomic nucleus, including stable isotopes such as zinc-64, zinc-66, zinc-67, zinc-68, and zinc-70, and radioactive isotopes such as zinc-65, zinc-71, and zinc-72.

Sulfur radioisotopes are unstable forms of the element sulfur that emit radiation as they decay into more stable forms. These isotopes can be used in medical imaging and treatment, such as in the detection and treatment of certain cancers. Common sulfur radioisotopes used in medicine include sulfur-35 and sulfur-32. Sulfur-35 is used in research and diagnostic applications, while sulfur-32 is used in brachytherapy, a type of internal radiation therapy. It's important to note that handling and usage of radioisotopes should be done by trained professionals due to the potential radiation hazards they pose.

Cadmium radioisotopes are unstable forms of the heavy metal cadmium that emit radiation as they decay into more stable elements. These isotopes can be created through various nuclear reactions, such as bombarding a cadmium atom with a high-energy particle. Some common cadmium radioisotopes include cadmium-109, cadmium-113, and cadmium-115.

These radioisotopes have a wide range of applications in medicine, particularly in diagnostic imaging and radiation therapy. For example, cadmium-109 is used as a gamma ray source for medical imaging, while cadmium-115 has been studied as a potential therapeutic agent for cancer treatment.

However, exposure to cadmium radioisotopes can also be hazardous to human health, as they can cause damage to tissues and organs through ionizing radiation. Therefore, handling and disposal of these materials must be done with care and in accordance with established safety protocols.

Astatine is a naturally occurring, radioactive, semi-metallic chemical element with the symbol At and atomic number 85. It is the rarest naturally occurring element in the Earth's crust, and the heaviest of the halogens. Astatine is not found free in nature, but is always found in combination with other elements, such as uranium and thorium.

Astatine is a highly reactive element that exists in several allotropic forms and is characterized by its metallic appearance and chemical properties similar to those of iodine. It has a short half-life, ranging from a few hours to a few days, depending on the isotope, and emits alpha, beta, and gamma radiation.

Due to its rarity, radioactivity, and short half-life, astatine has limited practical applications. However, it has been studied for potential use in medical imaging and cancer therapy due to its ability to selectively accumulate in tumors.

Microspheres are tiny, spherical particles that range in size from 1 to 1000 micrometers in diameter. They are made of biocompatible and biodegradable materials such as polymers, glass, or ceramics. In medical terms, microspheres have various applications, including drug delivery systems, medical imaging, and tissue engineering.

In drug delivery, microspheres can be used to encapsulate drugs and release them slowly over time, improving the efficacy of the treatment while reducing side effects. They can also be used for targeted drug delivery, where the microspheres are designed to accumulate in specific tissues or organs.

In medical imaging, microspheres can be labeled with radioactive isotopes or magnetic materials and used as contrast agents to enhance the visibility of tissues or organs during imaging procedures such as X-ray, CT, MRI, or PET scans.

In tissue engineering, microspheres can serve as a scaffold for cell growth and differentiation, promoting the regeneration of damaged tissues or organs. Overall, microspheres have great potential in various medical applications due to their unique properties and versatility.

Lutetium is a chemical element with the symbol Lu and atomic number 71. It is a rare earth metal that belongs to the lanthanide series. In its pure form, lutetium is a silvery-white metal that is solid at room temperature.

Medically, lutetium is used in the form of radioactive isotopes for diagnostic and therapeutic purposes. For example, lutetium-177 (^177Lu) is a radiopharmaceutical agent that can be used to treat certain types of cancer, such as neuroendocrine tumors. The radioactivity of ^177Lu can be harnessed to destroy cancer cells while minimizing damage to healthy tissue.

It's important to note that the use of lutetium in medical treatments should only be performed under the supervision of trained medical professionals, and with appropriate safety measures in place to protect patients and healthcare workers from radiation exposure.

The synovial membrane, also known as the synovium, is the soft tissue that lines the inner surface of the capsule of a synovial joint, which is a type of joint that allows for smooth movement between bones. This membrane secretes synovial fluid, a viscous substance that lubricates and nourishes the cartilage and helps to reduce friction within the joint during movement.

The synovial membrane has a highly specialized structure, consisting of two layers: the intima and the subintima. The intima is a thin layer of cells that are in direct contact with the synovial fluid, while the subintima is a more fibrous layer that contains blood vessels and nerves.

The main function of the synovial membrane is to produce and regulate the production of synovial fluid, as well as to provide nutrients to the articular cartilage. It also plays a role in the immune response within the joint, helping to protect against infection and inflammation. However, abnormalities in the synovial membrane can lead to conditions such as rheumatoid arthritis, where the membrane becomes inflamed and produces excess synovial fluid, leading to pain, swelling, and joint damage.

I'm sorry for any confusion, but "Rhenium" is not a medical term. It is a chemical element with the symbol "Re" and atomic number 75. Rhenium is a heavy, silvery-white, metallic element that is highly resistant to corrosion and is used in high-temperature alloys and electronics.

It does not have any direct medical relevance or application as a drug, treatment, or diagnostic tool in human medicine. However, like many other elements, rhenium compounds are being studied for their potential medicinal uses, such as in cancer therapy. But it's important to note that these are still in the research phase and have not yet been approved for use in humans.

Samarium is not a medical term itself, but it is a chemical element with the symbol Sm and atomic number 62. It is a silvery-white metallic element that belongs to the lanthanide series in the periodic table.

However, samarium-153 (Sm-153) is a radioactive isotope of samarium that has medical applications. It is used as a therapeutic agent for the treatment of painful bone metastases, particularly in patients with prostate or breast cancer. Sm-153 is combined with a chelating agent to form a complex that can be injected into the patient's bloodstream. The chelating agent helps to ensure that the samarium is distributed throughout the body and is not taken up by healthy tissues. Once inside the body, Sm-153 emits beta particles, which can destroy cancer cells in the bones and relieve pain.

Therefore, while samarium is not a medical term itself, it does have medical applications as a therapeutic agent for the treatment of bone metastases.

Monoclonal antibodies are a type of antibody that are identical because they are produced by a single clone of cells. They are laboratory-produced molecules that act like human antibodies in the immune system. They can be designed to attach to specific proteins found on the surface of cancer cells, making them useful for targeting and treating cancer. Monoclonal antibodies can also be used as a therapy for other diseases, such as autoimmune disorders and inflammatory conditions.

Monoclonal antibodies are produced by fusing a single type of immune cell, called a B cell, with a tumor cell to create a hybrid cell, or hybridoma. This hybrid cell is then able to replicate indefinitely, producing a large number of identical copies of the original antibody. These antibodies can be further modified and engineered to enhance their ability to bind to specific targets, increase their stability, and improve their effectiveness as therapeutic agents.

Monoclonal antibodies have several mechanisms of action in cancer therapy. They can directly kill cancer cells by binding to them and triggering an immune response. They can also block the signals that promote cancer growth and survival. Additionally, monoclonal antibodies can be used to deliver drugs or radiation directly to cancer cells, increasing the effectiveness of these treatments while minimizing their side effects on healthy tissues.

Monoclonal antibodies have become an important tool in modern medicine, with several approved for use in cancer therapy and other diseases. They are continuing to be studied and developed as a promising approach to treating a wide range of medical conditions.

Radiopharmaceuticals are defined as pharmaceutical preparations that contain radioactive isotopes and are used for diagnosis or therapy in nuclear medicine. These compounds are designed to interact specifically with certain biological targets, such as cells, tissues, or organs, and emit radiation that can be detected and measured to provide diagnostic information or used to destroy abnormal cells or tissue in therapeutic applications.

The radioactive isotopes used in radiopharmaceuticals have carefully controlled half-lives, which determine how long they remain radioactive and how long the pharmaceutical preparation remains effective. The choice of radioisotope depends on the intended use of the radiopharmaceutical, as well as factors such as its energy, range of emission, and chemical properties.

Radiopharmaceuticals are used in a wide range of medical applications, including imaging, cancer therapy, and treatment of other diseases and conditions. Examples of radiopharmaceuticals include technetium-99m for imaging the heart, lungs, and bones; iodine-131 for treating thyroid cancer; and samarium-153 for palliative treatment of bone metastases.

The use of radiopharmaceuticals requires specialized training and expertise in nuclear medicine, as well as strict adherence to safety protocols to minimize radiation exposure to patients and healthcare workers.

Radioactive soil pollutants refer to radioactive substances that contaminate and negatively impact the chemical, physical, and biological properties of soil. These pollutants can arise from various sources such as nuclear accidents, industrial activities, agricultural practices, and military testing. They include radionuclides such as uranium, plutonium, cesium-137, and strontium-90, among others.

Exposure to radioactive soil pollutants can have serious health consequences for humans and other living organisms. Direct contact with contaminated soil can result in radiation exposure, while ingestion or inhalation of contaminated soil particles can lead to internal radiation exposure. This can increase the risk of cancer, genetic mutations, and other health problems.

Radioactive soil pollutants can also have negative impacts on the environment, such as reducing soil fertility, disrupting ecosystems, and contaminating water sources. Therefore, it is essential to monitor and regulate radioactive soil pollution to protect human health and the environment.

Bromine radioisotopes are unstable forms of the element bromine that emit radiation as they decay into more stable forms. These isotopes can be used in various medical applications, such as diagnostic imaging and cancer treatment. Some commonly used bromine radioisotopes include Bromine-75, Bromine-76, and Bromine-77.

Bromine-75 is a positron-emitting radionuclide that can be used in positron emission tomography (PET) scans to image and diagnose various diseases, including cancer. It has a half-life of about 97 minutes.

Bromine-76 is also a positron-emitting radionuclide with a longer half-life of approximately 16.2 hours. It can be used in PET imaging to study the pharmacokinetics and metabolism of drugs, as well as for tumor imaging.

Bromine-77 is a gamma-emitting radionuclide with a half-life of about 57 hours. It can be used in various medical applications, such as in the labeling of antibodies and other biomolecules for diagnostic purposes.

It's important to note that handling and using radioisotopes require specialized training and equipment due to their potential radiation hazards.

Scintillation counting is a method used in medical physics and nuclear medicine to detect and quantify radioactivity. It relies on the principle that certain materials, known as scintillators, emit light flashes (scintillations) when they absorb ionizing radiation. This light can then be detected and measured to determine the amount of radiation present.

In a scintillation counting system, the sample containing radioisotopes is placed in close proximity to the scintillator. When radiation is emitted from the sample, it interacts with the scintillator material, causing it to emit light. This light is then detected by a photomultiplier tube (PMT), which converts the light into an electrical signal that can be processed and counted by electronic circuits.

The number of counts recorded over a specific period of time is proportional to the amount of radiation emitted by the sample, allowing for the quantification of radioactivity. Scintillation counting is widely used in various applications such as measuring radioactive decay rates, monitoring environmental radiation levels, and analyzing radioisotopes in biological samples.

A subdural effusion is an abnormal accumulation of fluid in the potential space between the dura mater (the outermost layer of the meninges that covers the brain and spinal cord) and the arachnoid membrane (one of the three layers of the meninges that surround the brain and spinal cord) in the subdural space.

Subdural effusions can occur due to various reasons, including head trauma, infection, or complications from neurosurgical procedures. The fluid accumulation may result from bleeding (subdural hematoma), inflammation, or increased cerebrospinal fluid pressure. Depending on the underlying cause and the amount of fluid accumulated, subdural effusions can cause various symptoms, such as headaches, altered mental status, or neurological deficits.

Subdural effusions are often asymptomatic and may resolve independently; however, in some cases, medical intervention might be necessary to alleviate the pressure on the brain or address the underlying condition. Imaging techniques like computed tomography (CT) or magnetic resonance imaging (MRI) scans are typically used to diagnose and monitor subdural effusions.

Calcium isotopes refer to variants of the chemical element calcium (ca) that have different numbers of neutrons in their atomic nuclei, and therefore differ in their atomic masses while having the same number of protons. The most common and stable calcium isotope is Calcium-40, which contains 20 protons and 20 neutrons. However, calcium has several other isotopes, including Calcium-42, Calcium-43, Calcium-44, and Calcium-46 to -52, each with different numbers of neutrons. Some of these isotopes are radioactive and decay over time. The relative abundances of calcium isotopes can vary in different environments and can provide information about geological and biological processes.

Radioactive waste is defined in the medical context as any material that contains radioactive nuclides in sufficient concentrations or for such durations that it is considered a threat to human health and the environment. It includes materials ranging from used hospital supplies, equipment, and substances contaminated with radionuclides, to liquids and gases released during the reprocessing of spent nuclear fuel.

Radioactive waste can be classified into two main categories:

1. Exempt waste: Waste that does not require long-term management as a radioactive waste due to its low activity and short half-life.
2. Radioactive waste: Waste that requires long-term management as a radioactive waste due to its higher activity or longer half-life, which can pose a threat to human health and the environment for many years.

Radioactive waste management is a critical aspect of nuclear medicine and radiation safety, with regulations in place to ensure proper handling, storage, transportation, and disposal of such materials.

Radio-iodinated serum albumin refers to human serum albumin that has been chemically bonded with radioactive iodine isotopes, typically I-125 or I-131. This results in a radiolabeled protein that can be used in medical imaging and research to track the distribution and movement of the protein in the body.

In human physiology, serum albumin is the most abundant protein in plasma, synthesized by the liver, and it plays a crucial role in maintaining oncotic pressure and transporting various molecules in the bloodstream. Radio-iodination of serum albumin allows for non-invasive monitoring of its behavior in vivo, which can be useful in evaluating conditions such as protein losing enteropathies, nephrotic syndrome, or liver dysfunction.

It is essential to handle and dispose of radio-iodinated serum albumin with proper radiation safety protocols due to its radioactive nature.

Ruthenium radioisotopes refer to unstable isotopes of the element ruthenium, which decays or disintegrates spontaneously emitting radiation. Ruthenium is a rare transition metal with the atomic number 44 and has several radioisotopes, including ruthenium-97, ruthenium-103, ruthenium-105, and ruthenium-106. These radioisotopes have medical applications in diagnostic imaging, radiation therapy, and brachytherapy (a type of internal radiation therapy).

For instance, ruthenium-106 is used as a radiation source in ophthalmic treatments for conditions such as neovascular age-related macular degeneration and diabetic retinopathy. Ruthenium-103 is also used in brachytherapy seeds for the treatment of prostate cancer.

It's important to note that handling and using radioisotopes require specialized training, equipment, and safety measures due to their radiation hazards.

Radiometric dating is a method used to determine the age of objects, including rocks and other fossilized materials, based on the decay rates of radioactive isotopes. This technique relies on the fact that certain elements, such as carbon-14, potassium-40, and uranium-238, are unstable and gradually decay into different elements over time.

By measuring the ratio of the remaining radioactive isotope to the stable end product, scientists can calculate the age of a sample using the following formula:

age = (ln(Nf/N0)) / λ

where Nf is the number of atoms of the decayed isotope, N0 is the initial number of atoms of the radioactive isotope, and λ is the decay constant.

Radiometric dating has been used to date objects ranging from a few thousand years old to billions of years old, making it an essential tool for archaeologists, geologists, and other scientists who study the history of our planet.

Selenium radioisotopes are unstable forms of the element selenium that emit radiation as they decay into more stable forms. These isotopes can be produced through various nuclear reactions, such as irradiating a stable selenium target with protons or alpha particles. Some examples of selenium radioisotopes include selenium-75, selenium-79, and selenium-81.

Selenium-75 is commonly used in medical imaging to study the function of the thyroid gland, as it accumulates in this gland and can be detected using a gamma camera. Selenium-79 and selenium-81 have potential uses in cancer treatment, as they can be incorporated into compounds that selectively target and destroy cancer cells. However, more research is needed to fully understand the potential benefits and risks of using these radioisotopes in medical treatments.

It's important to note that handling and using radioisotopes requires special training and precautions, as they can be dangerous if not handled properly. Exposure to radiation from radioisotopes can increase the risk of cancer and other health problems, so it's essential to use them only under controlled conditions and with appropriate safety measures in place.

Alpha particles are a type of radiation that consist of two protons and two neutrons. They are essentially the nuclei of helium atoms and are produced during the decay of radioactive isotopes, such as uranium or radon. When an alpha particle is emitted from a radioactive atom, it carries away energy and causes the atom to transform into a different element with a lower atomic number and mass number.

Alpha particles have a positive charge and are relatively massive compared to other types of radiation, such as beta particles (which are high-energy electrons) or gamma rays (which are high-energy photons). Because of their charge and mass, alpha particles can cause significant ionization and damage to biological tissue. However, they have a limited range in air and cannot penetrate the outer layers of human skin, making them generally less hazardous than other forms of radiation if exposure is external.

Internal exposure to alpha-emitting radionuclides, however, can be much more dangerous because alpha particles can cause significant damage to cells and DNA when they are emitted inside the body. This is why inhaling or ingesting radioactive materials that emit alpha particles can pose a serious health risk.

Heterocyclic compounds are organic molecules that contain a ring structure made up of at least one atom that is not carbon, known as a heteroatom. These heteroatoms can include nitrogen, oxygen, sulfur, or other elements. In the case of "1-ring" heterocyclic compounds, the molecule contains a single ring structure composed of these heteroatoms and carbon atoms. Examples of 1-ring heterocyclic compounds include pyridine (contains one nitrogen atom in the ring), furan (contains one oxygen atom in the ring), and thiophene (contains one sulfur atom in the ring). These compounds play important roles in various biological processes and are also found in many drugs, dyes, and materials.

Sodium Pertechnetate Tc 99m is a radioactive pharmaceutical preparation used in medical diagnostic imaging. It is a technetium-99m radiopharmaceutical, where technetium-99m is a metastable nuclear isomer of technetium-99, which emits gamma rays and has a half-life of 6 hours. Sodium Pertechnetate Tc 99m is used as a contrast agent in various diagnostic procedures, such as imaging of the thyroid, salivary glands, or the brain, to evaluate conditions like inflammation, tumors, or abnormalities in blood flow. It is typically administered intravenously, and its short half-life ensures that the radiation exposure is limited.

I'm sorry for any confusion, but 'Tungsten' is not a medical term. It is a chemical element with the symbol W and atomic number 74. Tungsten is a rare metal found naturally on Earth, and it has many industrial uses due to its hardness, high density, and high melting point.

In the context of medicine or healthcare, tungsten may be encountered in certain medical devices, such as X-ray tubes and electrodes, where its properties are utilized for their durability and heat resistance. However, it is not a term that would typically have a formal medical definition.

Isotopes are variants of a chemical element that have the same number of protons in their atomic nucleus, but a different number of neutrons. This means they have different atomic masses, but share similar chemical properties. Some isotopes are stable and do not decay naturally, while others are unstable and radioactive, undergoing radioactive decay and emitting radiation in the process. These radioisotopes are often used in medical imaging and treatment procedures.

Radioisotope teletherapy is a type of cancer treatment that uses high-energy radiation from a radioisotope to destroy cancer cells. In this procedure, the radioisotope is placed outside the body and aimed at the tumor site, rather than being inserted into the body like in brachytherapy. The radiation travels through space and penetrates the tissue to reach the tumor, where it damages the DNA of cancer cells and inhibits their ability to divide and grow. This type of radiotherapy is often used for larger or more difficult-to-reach tumors, as well as for palliative care in advanced stages of cancer. Examples of radioisotopes commonly used in teletherapy include cobalt-60 and cesium-137.

Pentetic Acid, also known as DTPA (Diethylenetriaminepentaacetic acid), is not a medication itself but a chelating agent used in the preparation of pharmaceutical products. A chelating agent is a compound that can form multiple bonds with metal ions, allowing them to be excreted from the body.

Pentetic Acid is used in medical treatments to remove or decrease the levels of certain toxic metals, such as lead, plutonium, americium, and curium, from the body. It can be given intravenously or orally, depending on the specific situation and the formulation of the medication.

It is important to note that the use of Pentetic Acid should be under the supervision of a healthcare professional, as it can also bind to essential metals like zinc, calcium, and iron, which can lead to deficiencies if not properly managed.

Investigation of yttrium-90 and other radioisotopes for cancer treatment began in the 1960s. Many key concepts, such as ... Clinical trials of yttrium-90 applied to the liver continued throughout the late 1980s to the 1990s, establishing the safety of ... Two of these use the radionuclide yttrium-90 (90Y) and are made of either glass (TheraSphere) or resin (SIR-Spheres). The third ... In the 1980s, the safety and feasibility of resin and glass yttrium-90 microsphere therapy for liver cancer were validated in a ...
It decays to yttrium-90, which is itself a beta emitter. It is also used as a thermal power source in radioisotope ... Nickel-63 is a radioisotope of nickel that can be used as an energy source in Radioisotope Piezoelectric Generators. It has a ... Khajepour, Abolhasan; Rahmani, Faezeh (1 January 2017). "An approach to design a 90Sr radioisotope thermoelectric generator ...
89Zr is a radioisotope of zirconium with a half-life of 78.41 hours. It is produced by proton irradiation of natural yttrium-89 ... The second most stable radioisotope is 93Zr, which has a half-life of 1.53 million years. Thirty other radioisotopes have been ... 93Zr is a radioisotope of zirconium with a half-life of 1.53 million years, decaying through emission of a low-energy beta ... 1019 y 88Zr is a radioisotope of zirconium with a half-life of 83.4 days. In January 2019, this isotope was discovered to have ...
1960s - Radioisotopes such as Yttrium-90 (Y90) started to be investigated for the use in cancer treatments. 1966 - Embolization ... "Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled ...
The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90, a radioisotope which destroys the ... Yttrium (90Y) tacatuzumab tetraxetan (trade name AFP-Cide) is a humanized monoclonal antibody intended for the treatment of ... Yttrium compounds, Experimental cancer drugs, DOTA (chelator) derivatives, All stub articles, Monoclonal antibody stubs, ...
Natural yttrium (39Y) is composed of a single isotope yttrium-89. The most stable radioisotopes are 88Y, which has a half-life ... Articles with short description, Short description with empty Wikidata description, Isotopes of yttrium, Yttrium, Lists of ... ISBN 978-0-8493-0485-9. E. V. Marathe (July 1955). "The Half-Life of Yttrium-90". Journal of Scientific & Industrial Research ( ... Fission product "Standard Atomic Weights: Yttrium". CIAAW. 2021. Prohaska, Thomas; Irrgeher, Johanna; Benefield, Jacqueline; et ...
In addition to Yttrium-90 (Y-90) and Rhenium-186 (Re-186), another radioisotope used in radiosynoviorthesis is Tin-117m (Sn- ... 117m). Tin-117m is radioisotope that is used to treat synovitis and osteoarthritis in canines with elbow dysplasia. Kampen, W. ...
The antibody part, clivatuzumab (targeted at MUC1), is conjugated with tetraxetan, a chelator for yttrium-90, a radioisotope ... Yttrium (90Y) clivatuzumab tetraxetan (trade name hPAM4-Cide) is a humanized monoclonal antibody-drug conjugate designed for ... "Statement On A Nonproprietary Name Adopted By The USAN Council: Yttrium Y90 clivatuzumab tetraxetan" (PDF). American Medical ... Yttrium compounds, All stub articles, Nuclear medicine stubs, Monoclonal antibody stubs, Antineoplastic and immunomodulating ...
Human application of the iodine radioisotopes required a more suitable radioisotope of iodine. Dr. Joseph Hamilton, a ... Yttrium-90 (Y-90) and Lutetium-177 are being used to diagnose and treat neuroendocrine tumors. The use of dosimetry has its ... Hertz." In the early 21st century, there is a significant rise in the use of radioisotopes to diagnose and treat cancer, in a ... Roberts also devised a Geiger-Müller detector for quantifying the amount of the radioisotope of iodine present in the ...
DOTA-biotin DOTA linked to the monoclonal antibody tacatuzumab and chelating yttrium-90 DOTATOC chelating yttrium-90 DOTA-TATE ... The resulting compounds are used with a number of radioisotopes in cancer therapy and diagnosis (for example in positron ... The remaining three carboxylate anions are available for binding to the yttrium ion. The modified antibody accumulates in the ... "Statement On A Nonproprietary Name Adopted By The USAN Council: Yttrium Y90 clivatuzumab tetraxetan" (PDF). American Medical ...
A major use of systemic radioisotope therapy is in the treatment of bone metastasis from cancer. The radioisotopes travel ... which is an anti-CD20 monoclonal antibody conjugated to yttrium-90. In 2003, the FDA approved the tositumomab/iodine (131I) ... Targeting can also be achieved by attaching the radioisotope to another molecule or antibody to guide it to the target tissue. ... The radioisotopes are delivered through infusion (into the bloodstream) or ingestion. Examples are the infusion of ...
... and delivers the radioisotope Yttrium-90 into the tumour. As of 2009[update], it is undergoing Phase III clinical trials. It ...
Longer-life radioisotopes, typically caesium-137 and strontium-90, present a long-term hazard. Intense beta radiation from the ... The induced isotopes include cobalt-60, 57 and 58, iron-59 and 55, manganese-54, zinc-65, yttrium-88, and possibly nickel-58 ... The bomb casing can be a significant sources of neutron-activated radioisotopes. The neutron flux in the bombs, especially ... The primary fallout hazard is gamma radiation from short-lived radioisotopes, which represent the bulk of activity. Within 24 ...
Pecher filed a patent in May 1941 for the synthesis of strontium-89 and yttrium-86 using cyclotrons, and described the ... 89Sr is an artificial radioisotope used in the treatment of osseous (bony) metastases of bone cancer. In circumstances where ... It undergoes β− decay into yttrium-89. Strontium-89 has an application in medicine. Strontium-89 was first synthesized in 1937 ...
... (INN) or 177Lu DOTA-TATE, trade name Lutathera, is a chelated complex of a radioisotope of the ... Alternatives to 177Lu-DOTATE include yttrium-90 DOTATATE or DOTATOC. The longer range of the beta particles emitted by 90Y, ...
Pecher filed a patent in May 1941 for the synthesis of strontium-89 and yttrium-86 using cyclotrons and described the use of ... For this reason, the metabolism of calcium attracted very early the interest of physicians looking for applying radioisotopes ... It was the third medical radioisotope, after phosphorus-32 and iodine-131 introduced respectively by John H. Lawrence and ... Pecher, Charles (1940). "A Long-Lived Isotope of Yttrium". Physical Review. 58 (9): 843. Bibcode:1940PhRv...58..843P. doi: ...
Trace elements, strontium and yttrium, were detected. The amount of potassium was one fifth of the average for the Earth's ... The Viking 2 lander was powered by radioisotope generators and operated on the surface until April 12, 1980, when its batteries ...
Non-mononuclidic elements are marked with an asterisk, and the long-lived primordial radioisotope given. In two cases (indium ... of radioactive rubidium-87 Yttrium-89 Niobium-93 Rhodium-103 Indium-113* naturally occurs with majority (95.7%) radioactive ...
Strontium-89 is an artificial radioisotope used in treatment of bone cancer; this application utilizes its chemical similarity ... Radioactive isotopes of strontium primarily decay into the neighbouring elements yttrium (89Sr and heavier isotopes, via beta ...
Van De Wiele C, Defreyne L, Peeters M, Lambert B (June 2009). "Yttrium-90 labelled resin microspheres for treatment of primary ... is a type of radioisotope therapy (RIT) in which a peptide or hormone conjugated to a radionuclide or radioligand is given ... The peptide receptor may be bound to lutetium-177, yttrium-90, indium-111 and other isotopes including alpha emitters. This is ... The mechanical targeting delivers the radiation from the yttrium-labeled microspheres selectively to the tumors without unduly ...
Yttrium and all lanthanides except Ce and Pm have been observed in the oxidation state 0 in bis(1,3,5-tri-t-butylbenzene) ... and one radioisotope, 152Gd, with the isotope 158Gd being the most abundant (24.8% natural abundance). The predicted double ... It can be manufactured in the same way as the most widely researched cuprate high temperature superconductor, yttrium barium ... Marshall, James L.; Marshall, Virginia R. (2008). "Rediscovery of the Elements: Yttrium and Johan Gadolin" (PDF). The Hexagon ( ...
In 1842 Mosander also separated the yttria into three oxides: pure yttria, terbia, and erbia (all the names are derived from ... Parts per million in earth's crust, e.g. Pb=13 ppm Promethium has no stable isotopes or primordial radioisotopes; trace ... and the yttrium earths (yttrium, dysprosium, holmium, erbium, thulium, ytterbium, and lutetium). Europium, gadolinium, and ... and those of the yttrium group are very soluble. Sometimes, the yttrium group was further split into the erbium group ( ...
96Zr has a half-life of 2.4×1019 years, and is the longest-lived radioisotope of zirconium. Of these natural isotopes, 90Zr is ... yttrium, lanthanum, and actinium. At room temperature zirconium exhibits a hexagonally close-packed crystal structure, α-Zr, ... usually composed of a mixture of zirconia and yttria. Zirconium-bearing compounds are used in many biomedical applications, ...
The decay of radioisotopes may limit the shelf life of a reagent, requiring its replacement and thus increasing expenses. ... This has been used for introducing Yttrium-90 onto a monoclonal antibody for therapeutic purposes and for introducing Gallium- ... It has the highest emission energy (1.7 MeV) of all common research radioisotopes. This is a major advantage in experiments for ... Replacing an atom with its own radioisotope is an intrinsic label that does not alter the structure of the molecule. ...
Twenty-five radioisotopes have been characterized with the most stable being 46Sc, which has a half-life of 83.8 days; 47Sc, ... Historically, it has been classified as a rare-earth element, together with yttrium and the lanthanides. It was discovered in ... Dentists use erbium-chromium-doped yttrium-scandium-gallium garnet (Er,Cr:YSGG) lasers for cavity preparation and in ... In early 2018, evidence was gathered from spectrometer data of significant scandium, vanadium, and yttrium abundances in red ...
Yttrium has no known biological role, and exposure to yttrium compounds can cause lung disease in humans. Zirconium is a ... The radioisotope iodine-131, which has a high fission product yield, concentrates in the thyroid, and is one of the most ... Elemental yttrium was first isolated in 1828 by Friedrich Wöhler. The most important use of yttrium is in making phosphors, ... Johan Gadolin discovered yttrium's oxide in Arrhenius' sample in 1789, and Anders Gustaf Ekeberg named the new oxide yttria. ...
He detected it as an impurity in yttrium oxide, Y2O3. Yttrium is named after the village of Ytterby in Sweden. Terbium was not ... Thirty-six radioisotopes have been characterized, with the heaviest being terbium-171 (with an atomic mass of 170.95330(86) u) ... He detected it as an impurity in yttrium oxide, Y2O3. Yttrium and terbium, as well as erbium and ytterbium, are named after the ... Yttrium and all lanthanides except Ce and Pm have been observed in the oxidation state 0 in bis(1,3,5-tri-t-butylbenzene) ...
They can be administered alone or be linked (conjugated) to anticancer drugs, radioisotopes, or other biologic response ... either yttrium-90 or indium-111) CD22. Approximately 85% of DLBCLs express CD22. It is expressed on pre-B and mature B cells, ...
Yttrium and all lanthanides except Ce and Pm have been observed in the oxidation state 0 in bis(1,3,5-tri-t-butylbenzene) ... Lanthanum telluride (La3Te4) is considered to be applied in the field of radioisotope power system (nuclear power plant) due to ... Scandium, Yttrium, Elements des Terres Rares, Actinium, P. Pascal, Editor, Masson & Cie, 1959 Chemistry of the Lanthanons, by R ... Naturally occurring lanthanum is made up of two isotopes, the stable 139La and the primordial long-lived radioisotope 138La. ...
This can be achieved by adding a yttrium deuteride moderator. For instance, plutonium can be reprocessed into mixed oxide fuels ... Some radioactive fission products can be converted into shorter-lived radioisotopes by transmutation. Transmutation of all ...
Yttrium-90 and Rhenium-188 Radiopharmaceuticals for Radionuclide Therapy. Radioisotopes and Radiopharmaceuticals Series No. 5 ... Radioisotopes and Radiopharmaceuticals Reports (1) Apply Radioisotopes and Radiopharmaceuticals Reports filter * (0) Apply ... Remove Radioisotopes and Radiopharmaceuticals Series filter Radioisotopes and Radiopharmaceuticals Series. *TECDOC Series (4) ... Remove Radioisotope Products and Radiation Technology Section filter Radioisotope Products and Radiation Technology Section ...
Investigation of yttrium-90 and other radioisotopes for cancer treatment began in the 1960s. Many key concepts, such as ... Clinical trials of yttrium-90 applied to the liver continued throughout the late 1980s to the 1990s, establishing the safety of ... Two of these use the radionuclide yttrium-90 (90Y) and are made of either glass (TheraSphere) or resin (SIR-Spheres). The third ... In the 1980s, the safety and feasibility of resin and glass yttrium-90 microsphere therapy for liver cancer were validated in a ...
Radioisotopes used are: Iodine 131 with 8.07 days half-life; Yttrium-90 β with 2.7 days half-life and Astatine-211 α with7.2 ... 2-the radioisotope selection and its interaction with tumor cells. The main advantage of RIT is reduction of late toxicity. It ...
Radioisotopes are placed into the cystic portions of the craniopharyngioma. Phosphorus-32 (32P), colloidal gold-198, colloidal ... yttrium-91, and bleomycin have all been used. Bleomycin causes shrinkage of the cyst but is highly toxic to neural structures. ...
Radiation segmentectomy (RS) is a minimally invasive option that uses the radioisotope yttrium-90 (Y90) to destroy tumours. ...
Sr-90 decays to yttrium 90 (Y-90), which in turn decays by beta radiation so that wherever Sr-90 is present Y-90 is also ...
Radioisotopes for medical use are perennially in short supply and their variety is certainly lacking, limiting their practical ... To address this, scientists at Polands National Centre for Nuclear Research developed novel methods of generating yttrium-90 ... Nuclear Scientists Devise New Methods to Produce Medical Radioisotopes. January 7th, 2013 Medgadget Editors etc., Oncology ... Radioisotopes for medical use are perennially in short supply and their variety is certainly lacking, limiting their practical ...
... refers to the infusion of microspheres of a radioisotope, yttrium-90, into the hepatic artery, and is also appropriate for ...
Lu-177 dotatate is more effective than a similar peptide receptor radionuclide therapy containing the radioisotope yttrium-90 ... "showing Lu-177 dotatate to be a very promising radioisotope, and we hope it gains approval," he commented. ...
... also known as transarterial radioembolization or selective internal radiation therapy with yttrium-90 (90Y) resin microspheres ...
rhenium186 is emerging as the preferred isotope over phosphorus32 and yttrium90 particularly in medium-sized joints 5 ... Radioisotope Synovectomy with Rhenium186 in Haemophilic Synovitis for Elbows, Ankles and Shoulders. Haemophilia. 2008;14(3):518 ... radioisotopes can be injected therapeutically into a joint to decrease bleeding and synovitis ...
Yttrium-90 radioisotope as a daughter of Strontium-90 is one of the nuclear fission products and plays an important role in the ... 22. W.Y. Skraba, H. Arino, H.H. Kramer, "A new 90Sr/90Y radioisotope generator," J. Appl. Radio & Isotope. 29, 91 (1978). ... 15. J.S. Wike, C.E. Guyer, D.W. Ramey, B.P. Pillips, "Chemistry for commercial scale production of yttrium-90 for medical ... Separation of yttrium and strontium was performed in the various simulation conditions and for determining the elements, ICP- ...
Keywords: Embolization, Therapeutic, Liver, Neuroendocrine Tumors, Yttrium Radioisotopes Abstract. Pancreatic neuroendocrine ... Selective internal radiotherapy with Yttrium-90microspheres for hepatic metastatic neuroendocrine tumors: a prospective single ... Radioembolization of symptomatic,unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc ...
... chemical binding of radioisotopes to L1 amino acids; and/or 4) chemical binding of radioisotopes to L1 and L2 amino acids. ... yttrium-90, iodine-131, phosphorus-32, boron-10, actinium-225, ismuth-213, lead-212, bismuth-212, polonium-212, thallium-208, ... Examples of radioisotopes that may be used with the methods described herein include, but are not limited to, lutetium-177 ( ... In some embodiments, radioisotopes are useful to treat cancer by killing cancer cells (for example by inducing apoptosis). In ...
Yttrium Radioisotopes. Weinsteins Networks Click the Explore. buttons for more information and interactive visualizations! ...
Radioisotope scanning using technetium (Tc) 99m may detect occult Kaposi sarcoma infiltration in the subcutaneous and muscular ... Similarly, classic Kaposi sarcoma may favorably respond to long-pulse neodymium-doped yttrium aluminum garnet laser therapy. [ ... Özdemir M, Balevi A. Successful Treatment of Classic Kaposi Sarcoma With Long-Pulse Neodymium-Doped Yttrium Aluminum Garnet (Nd ...
Radioisotopes of Yttrium, Zirconium, Columbium in the Bone Marrow, Liver and Spleen, ... Studies with Colloids Containing Radioisotopes of Yttrium, Zirconium, Columbium and Lanthaum: 2. The Controlled Selective ...
Yttrium Lithium Fluoride Lasers use Lasers, Solid-State Yttrium Radioisotopes Yttrium Scandium Gallium Garnet Lasers use Lasers ...
Yttrium Lithium Fluoride Lasers use Lasers, Solid-State Yttrium Radioisotopes Yttrium Scandium Gallium Garnet Lasers use Lasers ...
Yttrium Lithium Fluoride Lasers use Lasers, Solid-State Yttrium Radioisotopes Yttrium Scandium Gallium Garnet Lasers use Lasers ...
Yttrium Lithium Fluoride Lasers use Lasers, Solid-State Yttrium Radioisotopes Yttrium Scandium Gallium Garnet Lasers use Lasers ...
Yttrium Lithium Fluoride Lasers use Lasers, Solid-State Yttrium Radioisotopes Yttrium Scandium Gallium Garnet Lasers use Lasers ...
Radioisotopes are placed into the cystic portions of the craniopharyngioma. Phosphorus-32 (32 P), colloidal gold-198, colloidal ... yttrium-91, and bleomycin have all been used. Bleomycin causes shrinkage of the cyst but is highly toxic to neural structures. ...
Radioisotope-Based Insights. Based on radioisotope, the radiopharmaceutical theranostics market is divided into Lutetium (Lu) ... 177, Gallium-68, Iodine-131, Iodine-123, Technetium-99, Yttrium-90 (Y-90), Copper (Cu) 64, 18F, Copper (Cu) 67, and others. In ... Which radioisotope held the largest share in the radiopharmaceutical theranostics market? The Lutetium (Lu) 177 segment ... Radioisotopes emitting gamma rays are useful for diagnostic imaging where the radiation escapes the body. Nuclear medicine ...
The present invention also relates to antigen-binding proteins, or antigen-binding fragment conjugated to a radioisotope or ... binding protein or antigen-binding fragment comprising a radioisotope or cytotoxin conjugated thereto releases the radioisotope ... yttrium90 and lutetium177. Methods for preparing radioimmunconjugates are established in the art. Examples of ... The antigen-binding protein, or an antigen-binding fragment thereof, as claimed in claim 34, comprising a radioisotope or a ...
7. By Radioisotopes. 7.1. Introduction. 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes Segment. ... Yttrium 90 7.7. Gallium 68 7.8. Gallium 67 7.9. Rubidium 82 7.10. Iodine 123 7.11. Iodine 125 7.12. Indium 111. 7.13. Others 8 ... 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes. 11.2.4. Market Size Analysis, and Y-o-Y Growth ... 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes. 11.3.4. Market Size Analysis, and Y-o-Y Growth ...
Radioisotope scanning using technetium-99m may detect occult KS infiltration in the subcutaneous and muscular tissues and ... Özdemir M, Balevi A. Successful Treatment of Classic Kaposi Sarcoma With Long-Pulse Neodymium-Doped Yttrium Aluminum Garnet (Nd ... Argon laser photocoagulation therapy also may be successful in classic KS lesions; long-pulse neodymium-doped yttrium aluminum ...
I-131 and certain other clinically used radioisotopes (notably lutetium-177, samarium-153, and yttrium-90) are emitters of beta ... The yttrium-labeled anti-CD20 antibodies Zevalin and Bexxar were approved by the FDA in 2002 and 2003; while highly effective, ... radiopharmaceuticals combine a radioisotope with a targeting molecule that binds a specific tumor protein or selectively ... which include nine possible choices based on certain radioisotopes of actinium, bismuth, lead, radium, terbium, or thorium). ...
Yttrium Radioisotopes. © 2023 Offices of the Nuffield Professor of Medicine, Nuffield Department of Medicine, University of ...
  • To address this, scientists at Poland's National Centre for Nuclear Research developed novel methods of generating yttrium-90 and lutetium-177, precursors for isotopes that would be used in medicine. (medgadget.com)
  • I-131 and certain other clinically used radioisotopes (notably lutetium-177, samarium-153, and yttrium-90) are emitters of beta particle radiation. (bionest.com)
  • Besides Actinium-225, Eckert & Ziegler also supplies international pharmaceutical companies with Lutetium-177, Gallium-68, Yttrium-90 and other radioisotopes that are essential for use in diagnostics and therapy. (ezag.com)
  • The most commonly used radionuclides in targeted radiotherapy are beta-emitters, specifically: Yttrium-90 (90Y), Iodine-131 (131I), and Lutetium-177 (177Lu). (unife.it)
  • Experts expect that the emergence of highly effective cancer radiotherapeutics for neuroendocrine tumors, prostate cancer and further radiopharmaceuticals currently under development will significantly increase demand for the radioisotopes Yttrium-90, Lutetium-177 and Gallium-68 in China and globally. (ezag.com)
  • Examples are the infusion of metaiodobenzylguanidine (MIBG) to treat neuroblastoma , of oral iodine-131 to treat thyroid cancer or thyrotoxicosis , and of hormone-bound lutetium-177 and yttrium-90 to treat neuroendocrine tumors (peptide receptor radionuclide therapy). (drdehghanmanshadi.com)
  • Background: Radioembolization, also known as transarterial radioembolization or selective internal radiation therapy with yttrium-90 (90Y) resin microspheres, is an established treatment modality for patients with primary and secondary liver tumors. (unav.edu)
  • Radioembolization of symptomatic,unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. (unina.it)
  • Another example is the injection of yttrium-90 radioactive glass or resin microspheres into the hepatic artery to radioembolize liver tumors or liver metastases. (drdehghanmanshadi.com)
  • Dr. Loaiza-Bonilla posed the question of whether Lu-177 dotatate is more effective than a similar peptide receptor radionuclide therapy containing the radioisotope yttrium-90. (ascopost.com)
  • This evidence, following the clinical experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors, has suggested that somatostatin analogs, coupled with appropriate radioisotopes, might also be of value in the treatment of brain tumors. (unife.it)
  • The Nuclear Regulatory Commission has proposed an $8,750 fine to VHS Harper-Hutzel Hospital in Detroit, Michigan, for two violations of NRC safety requirements during the administrations of radioisotopes for treatment of liver tumors. (tmia.com)
  • The Impact of Injection Distance to Bifurcations on Yttrium-90 Distribution in Liver Cancer Radioembolization. (ucdavis.edu)
  • The hospital holds an NRC license for the use of nuclear material for diagnostic and therapeutic nuclear medicine and for yttrium-90 (Y-90) microsphere administrations. (tmia.com)
  • This chelator conjugated antibody can be linked to different radioisotopes for diagnostic ( 89 Zirconium) or therapeutic purposes ( 177 Lutetium, 111 Indium or 90 Yttrium) [5, 6]. (memoinoncology.com)
  • Radioisotopes emitting gamma radiation are preferable in diagnostic applications, whereas in therapeutic applications, beta emitters are used. (hygeia.gr)
  • Optical radiation hazards associated with the use of neodymium yttrium aluminum garnet lasers were investigated. (cdc.gov)
  • Selective internal radiotherapy with Yttrium-90microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. (unina.it)
  • The crystals, such as gadolinium gallium garnet and yttrium gallium garnet, are grown by melting pre-sintered charges of mixed oxides under oxidizing conditions at temperatures up to 2100 °C. (refractorymetal.org)
  • We also distribute a range of other isotopes used in radiopharmacy around the world, including iodine, yttrium and gallium for example. (transrad.be)
  • Yttrium-90 radioisotope as a daughter of Strontium-90 is one of the nuclear fission products and plays an important role in the treatment of malignant tumors in nuclear medicine. (nstri.ir)
  • Studies with Colloids Containing Radioisotopes of Yttrium, Zirconium, Columbium and Lanthaum: 2. (europa.eu)
  • Similar to targeted therapies that deliver an effector drug to a specific tumor via an antigen or cellular receptor, radiopharmaceuticals combine a radioisotope with a targeting molecule that binds a specific tumor protein or selectively accumulates within a specific tissue. (bionest.com)
  • As a result, attention has increasingly turned to another class of isotopes, alpha particle emitters (which include nine possible choices based on certain radioisotopes of actinium, bismuth, lead, radium, terbium, or thorium). (bionest.com)
  • The responsible authorities approved QKM's planned construction of a radioisotope production facility consisting of clean rooms for sealed and non-sealed radioactive material, laboratories for quality control and microbiology. (ezag.com)
  • A major use of systemic radioisotope therapy is in the treatment of bone metastasis from cancer. (drdehghanmanshadi.com)
  • The radioisotope emits powerful, high-energy alpha particles with short penetration depths that enable precise treatment of tumor cells with minimal impact on surrounding healthy tissue. (ezag.com)
  • The term "open sources" refers to substances labeled with radioisotopes that are administered intravenously or orally to the patient, in order to obtain information on the function and metabolism of the human body organs or for the treatment of certain diseases. (hygeia.gr)
  • This leads to an additional term in the free en- ergy per molecule of kT log(2SA 1)(2SB 1), and to a contribution of k log(2SA 1)(2SB 1) to the forex bse, i. 151. (binaryoptionstradinglist.com)
  • Targeting can also be achieved by attaching the radioisotope to another molecule or antibody to guide it to the target tissue. (drdehghanmanshadi.com)
  • Radiation segmentectomy (RS) is a minimally invasive option that uses the radioisotope yttrium-90 (Y90) to destroy tumours. (asianage.com)
  • Sr-90 decays to yttrium 90 (Y-90), which in turn decays by beta radiation so that wherever Sr-90 is present Y-90 is also present. (cdc.gov)
  • Particulate radiation (usually beta particles) emitted by the radioisotope kill or damage the tumor cells. (wustl.edu)
  • In general, the radioisotopes used in nuclear medicine decay emitting either gamma or beta radiation, or, in some cases, both. (hygeia.gr)
  • The radioisotopes travel selectively to areas of damaged bone, and spare normal undamaged bone. (drdehghanmanshadi.com)
  • In 2002, the United States Food and Drug Administration (FDA) approved ibritumomab tiuxetan (Zevalin), which is an anti- CD20 monoclonal antibody conjugated to yttrium-90. (drdehghanmanshadi.com)
  • Compatible with PET images acquired with another radioisotope (correction of branching ratio and decay parameters). (itnonline.com)
  • 5 The results led to the NETTER-1 study, "showing Lu-177 dotatate to be a very promising radioisotope, and we hope it gains approval," he commented. (ascopost.com)
  • Moreover, potential radioisotopes in the pipeline, cyclotron based production are likely to create huge opportunities for this market in the coming years. (gosreports.com)
  • June 20, 2019 - DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet Onco Dose software for its oncology and yttrium-90 (Y-90) microsphere SIRT 3-D dosimetry components. (itnonline.com)
  • This radioisotope is used in almost 80% of in vivo diagnostics. (transrad.be)
  • With our own production we will become one of the first commercial suppliers to make the radioisotope available globally. (ezag.com)
  • This graph shows the total number of publications written about "Cesium Radioisotopes" by people in this website by year, and whether "Cesium Radioisotopes" was a major or minor topic of these publications. (ucdenver.edu)
  • Radioisotopes for medical use are perennially in short supply and their variety is certainly lacking, limiting their practical use in a variety of cancers. (medgadget.com)
  • Cesium Radioisotopes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (ucdenver.edu)
  • Below are the most recent publications written about "Cesium Radioisotopes" by people in Profiles. (ucdenver.edu)